<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>acute.sustained_animal</th>
      <th>sample.group.size_intervention_animal</th>
      <th>outcome.count_intervention_animal</th>
      <th>outcome.direction_animal</th>
      <th>gnotobiotic</th>
      <th>animal.strain</th>
      <th>animal.sex</th>
      <th>species</th>
      <th>success.measure</th>
      <th>p.t.intervention_animal</th>
      <th>ribotype</th>
      <th>c.diff.strain</th>
      <th>animal.age.value..days.</th>
      <th>animal.weight.value..g.</th>
      <th>c.diff.dose.value</th>
      <th>c.diff.dose.units</th>
      <th>c.diff.dose.vegetative.spores</th>
      <th>daily.dosage_intervention_animal</th>
      <th>total.dosage_intervention_animal</th>
      <th>comparator_animal</th>
      <th>p.t.comparator_animal</th>
      <th>sample.group.size_comparator_animal</th>
      <th>outcome.count_comparator_animal</th>
      <th>daily.dosage_comparator_animal</th>
      <th>total.dosage_comparator_animal</th>
      <th>hash</th>
      <th>s.estimate_animal</th>
      <th>s.p.value_animal</th>
      <th>i.p.estimate_animal</th>
      <th>i.p.value_animal</th>
      <th>acute.sustained_human</th>
      <th>daily.dosage.intervention_human</th>
      <th>total.dosage.intervention_human</th>
      <th>dosage.value</th>
      <th>dosage.units</th>
      <th>dosage.times.per.day</th>
      <th>dosage.duration</th>
      <th>dosage.comment</th>
      <th>intervention.class</th>
      <th>intervention_human</th>
      <th>dose.dependence</th>
      <th>sample.group.size_intervention_human</th>
      <th>p.t.human</th>
      <th>outcome</th>
      <th>outcome.direction_human</th>
      <th>measure.description</th>
      <th>outcome.group.size</th>
      <th>author.conclusion</th>
      <th>conclusion.method</th>
      <th>Gender</th>
      <th>Age.Groups</th>
      <th>Age.Description</th>
      <th>Phases</th>
      <th>outcome.count_intervention_human</th>
      <th>comparator.class</th>
      <th>sample.group.size_comparator_human</th>
      <th>outcome.count_comparator_human</th>
      <th>daily.dosage.comparator_human</th>
      <th>total.dosage.comparator_human</th>
      <th>s.estimate_human</th>
      <th>s.p.value_human</th>
      <th>i.p.estimate_human</th>
      <th>i.p.value_human</th>
      <th>exact_translation</th>
      <th>relative_translation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25.0,25486992,27.0,4,49.0,5,5.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.266667</td>
      <td>2.065317e-01</td>
      <td>0.266667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25.0,25486992,27.0,4,49.0,5,5.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.266667</td>
      <td>2.065317e-01</td>
      <td>0.266667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>2</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25.0,25486992,27.0,4,49.0,5,5.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.266667</td>
      <td>2.065317e-01</td>
      <td>0.266667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>3</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25.0,25486992,27.0,4,49.0,5,5.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.266667</td>
      <td>2.065317e-01</td>
      <td>0.266667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>101</td>
      <td>therapeutic</td>
      <td>Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>control</td>
      <td>99</td>
      <td>25</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.183218</td>
      <td>1.000000</td>
      <td>-0.183218</td>
      <td>0.000223</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>4</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25.0,25486992,27.0,4,49.0,5,5.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.266667</td>
      <td>2.065317e-01</td>
      <td>0.266667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>5</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25.0,25486992,27.0,4,49.0,5,5.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.700000</td>
      <td>9.095780e-03</td>
      <td>0.700000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>6</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25.0,25486992,27.0,4,49.0,5,5.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.700000</td>
      <td>9.095780e-03</td>
      <td>0.700000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>7</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25.0,25486992,27.0,4,49.0,5,5.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.700000</td>
      <td>9.095780e-03</td>
      <td>0.700000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>8</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25.0,25486992,27.0,4,49.0,5,5.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.700000</td>
      <td>9.095780e-03</td>
      <td>0.700000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>101</td>
      <td>therapeutic</td>
      <td>Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>control</td>
      <td>99</td>
      <td>25</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.183218</td>
      <td>1.000000</td>
      <td>-0.183218</td>
      <td>0.000223</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>9</th>
      <td>sustained</td>
      <td>5</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25.0,25486992,27.0,4,49.0,5,5.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.700000</td>
      <td>9.095780e-03</td>
      <td>0.700000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>10</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25486992,27.0,49.0,5,5,50.0,50.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.466667</td>
      <td>3.550283e-02</td>
      <td>0.466667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>11</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25486992,27.0,49.0,5,5,50.0,50.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.466667</td>
      <td>3.550283e-02</td>
      <td>0.466667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>12</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25486992,27.0,49.0,5,5,50.0,50.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.466667</td>
      <td>3.550283e-02</td>
      <td>0.466667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>13</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25486992,27.0,49.0,5,5,50.0,50.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.466667</td>
      <td>3.550283e-02</td>
      <td>0.466667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>101</td>
      <td>therapeutic</td>
      <td>Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>control</td>
      <td>99</td>
      <td>25</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.183218</td>
      <td>1.000000</td>
      <td>-0.183218</td>
      <td>0.000223</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>14</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>15</td>
      <td>8</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>100000.0,15,2015,25486992,27.0,49.0,5,5,50.0,50.0,8,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,p,positive,spores,survival,sustained,t</td>
      <td>0.466667</td>
      <td>3.550283e-02</td>
      <td>0.466667</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>15</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25486992,27.0,49.0,5,5,50.0,50.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.900000</td>
      <td>4.758628e-04</td>
      <td>0.900000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>16</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25486992,27.0,49.0,5,5,50.0,50.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.900000</td>
      <td>4.758628e-04</td>
      <td>0.900000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>17</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25486992,27.0,49.0,5,5,50.0,50.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.900000</td>
      <td>4.758628e-04</td>
      <td>0.900000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>18</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25486992,27.0,49.0,5,5,50.0,50.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.900000</td>
      <td>4.758628e-04</td>
      <td>0.900000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>101</td>
      <td>therapeutic</td>
      <td>Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>control</td>
      <td>99</td>
      <td>25</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.183218</td>
      <td>1.000000</td>
      <td>-0.183218</td>
      <td>0.000223</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>19</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>UK1</td>
      <td>49.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1,10,100000.0,2015,25486992,27.0,49.0,5,5,50.0,50.0,C57BL/6,UK1,actoxumab-bezlotoxumab,control,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,nan,positive,spores,survival,sustained,t,t</td>
      <td>0.900000</td>
      <td>4.758628e-04</td>
      <td>0.900000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>actoxumab-bezlotoxumab</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>20</th>
      <td>sustained</td>
      <td>12</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>63.0</td>
      <td>NaN</td>
      <td>10000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>50.00</td>
      <td>50.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>12</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>10000.0,12,12,18848941,2008,5,50.0,50.0,6,63.0,87.0,C57BL/6,CFU,F,VPI 10463,control,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,nan,nan,nan,p,p,positive,sustained,vancomycin</td>
      <td>-0.083333</td>
      <td>9.998800e-01</td>
      <td>-0.083333</td>
      <td>4.194099e-01</td>
      <td>sustained</td>
      <td>125.0</td>
      <td>NaN</td>
      <td>125</td>
      <td>mg</td>
      <td>QD</td>
      <td>NaN</td>
      <td>unspecified duration</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>17</td>
      <td>prophylactic</td>
      <td>Clostridium Difficile Infection Occurrence [ Time Frame: Within 4 weeks from the completion of antibiotic treatment ]</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Older Adult</td>
      <td>65 Years and older Â (Older Adult)</td>
      <td>Phase 4</td>
      <td>0</td>
      <td>control</td>
      <td>34</td>
      <td>2</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.058824</td>
      <td>0.220013</td>
      <td>-0.058824</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>21</th>
      <td>sustained</td>
      <td>15</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>80.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,20.0,2006,4,75.0,80.0,82,87.0,CFU,Golden Syrian,MDX1388,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.047154</td>
      <td>6.008476e-01</td>
      <td>0.047154</td>
      <td>9.998500e-01</td>
      <td>sustained</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>MDX1388</td>
      <td>no</td>
      <td>390</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>14.9</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>58</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.107896</td>
      <td>0.000109</td>
      <td>-0.107896</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>22</th>
      <td>sustained</td>
      <td>15</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>80.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,20.0,2006,4,75.0,80.0,82,87.0,CFU,Golden Syrian,MDX1388,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.047154</td>
      <td>6.008476e-01</td>
      <td>0.047154</td>
      <td>9.998500e-01</td>
      <td>sustained</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>MDX1388</td>
      <td>no</td>
      <td>390</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>14.9</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>58</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.107896</td>
      <td>0.000109</td>
      <td>-0.107896</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>23</th>
      <td>sustained</td>
      <td>15</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>80.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,20.0,2006,4,75.0,80.0,82,87.0,CFU,Golden Syrian,MDX1388,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.047154</td>
      <td>6.008476e-01</td>
      <td>0.047154</td>
      <td>9.998500e-01</td>
      <td>sustained</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>MDX1388</td>
      <td>no</td>
      <td>390</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>14.9</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>58</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.107896</td>
      <td>0.000109</td>
      <td>-0.107896</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>24</th>
      <td>sustained</td>
      <td>15</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>80.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,20.0,2006,4,75.0,80.0,82,87.0,CFU,Golden Syrian,MDX1388,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.047154</td>
      <td>6.008476e-01</td>
      <td>0.047154</td>
      <td>9.998500e-01</td>
      <td>sustained</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>MDX1388</td>
      <td>no</td>
      <td>390</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>14.9</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>58</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.107896</td>
      <td>0.000109</td>
      <td>-0.107896</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>25</th>
      <td>sustained</td>
      <td>22</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>80.00</td>
      <td>320.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,2006,22,320.0,75.0,80.0,82,87.0,CDA1 + MDX1388,CFU,Golden Syrian,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.462306</td>
      <td>1.325038e-04</td>
      <td>0.462306</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>CDA1 + MDX1388</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>26</th>
      <td>sustained</td>
      <td>22</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>80.00</td>
      <td>320.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,2006,22,320.0,75.0,80.0,82,87.0,CDA1 + MDX1388,CFU,Golden Syrian,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.462306</td>
      <td>1.325038e-04</td>
      <td>0.462306</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>CDA1 + MDX1388</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>27</th>
      <td>sustained</td>
      <td>22</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>80.00</td>
      <td>320.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,2006,22,320.0,75.0,80.0,82,87.0,CDA1 + MDX1388,CFU,Golden Syrian,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.462306</td>
      <td>1.325038e-04</td>
      <td>0.462306</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>CDA1 + MDX1388</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>28</th>
      <td>sustained</td>
      <td>22</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>80.00</td>
      <td>320.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,2006,22,320.0,75.0,80.0,82,87.0,CDA1 + MDX1388,CFU,Golden Syrian,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.462306</td>
      <td>1.325038e-04</td>
      <td>0.462306</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>CDA1 + MDX1388</td>
      <td>no</td>
      <td>101</td>
      <td>therapeutic</td>
      <td>Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>control</td>
      <td>99</td>
      <td>25</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.183218</td>
      <td>1.000000</td>
      <td>-0.183218</td>
      <td>0.000223</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>29</th>
      <td>sustained</td>
      <td>22</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>80.00</td>
      <td>320.00</td>
      <td>control</td>
      <td>therapeutic</td>
      <td>82</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>140000.0,15,16966409,18,2006,22,320.0,75.0,80.0,82,87.0,CDA1 + MDX1388,CFU,Golden Syrian,VPI 10463,clindamycin+challenge+vancomycin,control,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.462306</td>
      <td>1.325038e-04</td>
      <td>0.462306</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>CDA1 + MDX1388</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.7</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>62</td>
      <td>control</td>
      <td>378</td>
      <td>97</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>-0.099652</td>
      <td>0.000334</td>
      <td>-0.099652</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>30</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2014,24277020,3,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>31</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2014,24277020,3,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>32</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2014,24277020,3,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>33</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2014,24277020,3,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>34</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>35</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>36</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>37</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>38</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>39</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>40</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>41</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>42</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>43</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>44</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>45</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>46</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,150.0,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>47</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,150.0,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>48</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,150.0,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>49</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,150.0,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>50</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>51</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>52</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>53</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>54</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>55</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>56</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>57</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>58</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>59</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>60</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>61</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>62</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>63</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>64</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>65</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>66</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>67</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>68</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>69</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>70</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>71</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>72</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>73</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>74</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>75</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>76</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>77</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>78</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>79</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>80</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>81</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>82</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>83</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>84</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>85</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>86</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>87</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>88</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>89</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>90</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>91</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>92</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>93</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>94</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>95</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>96</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>97</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>98</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>99</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>100</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>101</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>102</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>103</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>104</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>105</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>106</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100000.0,111.0,12.5,12.5,2014,24277020,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>107</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100000.0,111.0,12.5,12.5,2014,24277020,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>108</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100000.0,111.0,12.5,12.5,2014,24277020,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>109</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100000.0,111.0,12.5,12.5,2014,24277020,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>110</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>111</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>112</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>113</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>114</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>115</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>116</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>117</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>118</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>119</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>120</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>121</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>122</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>123</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>124</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>125</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>126</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>127</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>128</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>129</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>130</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>131</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>132</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>133</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>134</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>135</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>136</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>137</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>138</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>139</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>140</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>141</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>142</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>143</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>144</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>145</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>146</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>147</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>148</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>149</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>150</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,15.0,2014,24277020,3.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>151</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,15.0,2014,24277020,3.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>152</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,15.0,2014,24277020,3.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>153</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,15.0,2014,24277020,3.0,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>154</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,150.0,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>155</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,150.0,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>156</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,150.0,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>157</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,150.0,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>158</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>159</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>160</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>161</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>162</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>163</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>164</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>165</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>166</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,20,2014,24277020,30.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>167</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,20,2014,24277020,30.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>168</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,20,2014,24277020,30.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>169</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,20,2014,24277020,30.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>170</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>171</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>172</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>173</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>174</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100000.0,111.0,150.0,20,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>175</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100000.0,111.0,150.0,20,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>176</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100000.0,111.0,150.0,20,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>177</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100000.0,111.0,150.0,20,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>0.000000</td>
      <td>9.998001e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>178</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>179</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>180</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>181</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>182</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>183</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>184</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>185</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>186</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>187</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>188</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>189</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>190</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.376381</td>
      <td>3.924218e-02</td>
      <td>0.376381</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>191</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.376381</td>
      <td>3.924218e-02</td>
      <td>0.376381</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>192</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.376381</td>
      <td>3.924218e-02</td>
      <td>0.376381</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>193</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.376381</td>
      <td>3.924218e-02</td>
      <td>0.376381</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>194</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,15,17,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.415063</td>
      <td>1.000000e+00</td>
      <td>-0.415063</td>
      <td>6.399342e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>195</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,15,17,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.415063</td>
      <td>1.000000e+00</td>
      <td>-0.415063</td>
      <td>6.399342e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>196</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,15,17,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.415063</td>
      <td>1.000000e+00</td>
      <td>-0.415063</td>
      <td>6.399342e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>197</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,15,17,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.415063</td>
      <td>1.000000e+00</td>
      <td>-0.415063</td>
      <td>6.399342e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>198</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,11,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>8.568601e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>199</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,11,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>8.568601e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>200</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,11,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>8.568601e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>201</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,11,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>8.568601e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>202</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,110,114,15,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.082559</td>
      <td>1.242284e-01</td>
      <td>0.082559</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>203</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,110,114,15,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.082559</td>
      <td>1.242284e-01</td>
      <td>0.082559</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>204</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,110,114,15,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.082559</td>
      <td>1.242284e-01</td>
      <td>0.082559</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>205</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>15</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,110,114,15,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.082559</td>
      <td>1.242284e-01</td>
      <td>0.082559</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>206</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,11,11,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>4.722590e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>207</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,11,11,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>4.722590e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>208</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,11,11,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>4.722590e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>209</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,11,11,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>4.722590e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>210</th>
      <td>acute</td>
      <td>107</td>
      <td>107</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,107,11,11,20.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.8 (79.2 to 87.5)</td>
      <td>Non-Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>253</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>270</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.011308</td>
      <td>0.996994</td>
      <td>-0.011308</td>
      <td>0.392520</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>211</th>
      <td>acute</td>
      <td>107</td>
      <td>107</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,107,11,11,20.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.077540</td>
      <td>0.319059</td>
      <td>0.077540</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>212</th>
      <td>acute</td>
      <td>107</td>
      <td>107</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,107,11,11,20.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.036364</td>
      <td>0.410568</td>
      <td>0.036364</td>
      <td>0.999800</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>213</th>
      <td>acute</td>
      <td>107</td>
      <td>107</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>11</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,107,11,11,20.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>0.000000</td>
      <td>9.998900e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>19</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.021531</td>
      <td>0.999810</td>
      <td>-0.021531</td>
      <td>0.466658</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>214</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>215</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>216</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>217</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>218</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>219</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>220</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,4,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>221</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,4,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>222</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,4,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>223</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,4,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>224</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,4,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>225</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,4,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>226</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>227</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>228</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>229</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>230</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>231</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>232</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>233</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>234</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>235</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>236</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>237</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>238</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>239</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>240</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>241</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>242</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>243</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>244</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>245</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>246</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>247</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>248</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>249</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,30.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>250</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>251</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>252</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>253</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>254</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>255</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,4,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>256</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>257</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>258</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>259</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>260</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>261</th>
      <td>acute</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>262</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10,10,10.0,100.0,100000.0,111.0,2014,24277020,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>263</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10,10,10.0,100.0,100000.0,111.0,2014,24277020,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>264</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10,10,10.0,100.0,100000.0,111.0,2014,24277020,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>265</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10,10,10.0,100.0,100000.0,111.0,2014,24277020,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>266</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10,10,10.0,100.0,100000.0,111.0,2014,24277020,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>267</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10,10,10.0,100.0,100000.0,111.0,2014,24277020,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>268</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>269</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>270</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>271</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>272</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>273</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,10.0,100000.0,111.0,12.5,2014,24277020,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>274</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>275</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>276</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>277</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>278</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>279</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>280</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>281</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>282</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>283</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>284</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>285</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>286</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>287</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>288</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>289</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>290</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>291</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>292</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>293</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>294</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>295</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>296</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>297</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>298</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>299</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>300</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>301</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>302</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>303</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,100000.0,111.0,2014,24277020,250.0,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>304</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>305</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>306</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>307</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>308</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>309</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10,10,100.0,100000.0,111.0,12.5,2014,24277020,500.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>310</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>311</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>312</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>313</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>314</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>315</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>316</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>317</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>318</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>319</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>320</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>321</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>322</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>323</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>324</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>325</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>326</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>327</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,20,2014,24277020,30.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>328</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>329</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>330</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>331</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>332</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>333</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>334</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>335</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>336</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>337</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>338</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>339</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,100000.0,111.0,2014,24277020,250.0,50.0,500.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>340</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>341</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>342</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>343</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>344</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>345</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>346</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>347</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>348</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>349</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>350</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>351</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>352</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>353</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>354</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>355</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>356</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>357</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>358</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>359</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>360</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>361</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>362</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>363</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>364</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>365</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>366</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>367</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>368</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>369</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>370</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>371</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>372</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>373</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>374</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>375</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>376</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>377</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>378</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>379</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>380</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>381</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>382</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>383</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>384</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>385</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>386</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>387</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>388</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>389</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>390</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>391</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>392</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>393</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>394</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>395</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>396</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>397</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>398</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>399</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>400</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>401</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>402</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>403</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>404</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>405</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>406</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>407</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>408</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>409</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>410</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>411</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>412</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>413</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>414</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>415</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>416</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>417</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,20,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>418</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>419</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>420</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>421</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>422</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>423</th>
      <td>acute</td>
      <td>20</td>
      <td>20</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>424</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>425</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>426</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>427</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>428</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>429</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>430</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,110,114,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.497623</td>
      <td>1.000000e+00</td>
      <td>-0.497623</td>
      <td>1.213588e-17</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>431</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,110,114,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.497623</td>
      <td>1.000000e+00</td>
      <td>-0.497623</td>
      <td>1.213588e-17</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>432</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,110,114,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.497623</td>
      <td>1.000000e+00</td>
      <td>-0.497623</td>
      <td>1.213588e-17</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>433</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,110,114,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.497623</td>
      <td>1.000000e+00</td>
      <td>-0.497623</td>
      <td>1.213588e-17</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>434</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,110,114,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.497623</td>
      <td>1.000000e+00</td>
      <td>-0.497623</td>
      <td>1.213588e-17</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>435</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,110,114,2.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.497623</td>
      <td>1.000000e+00</td>
      <td>-0.497623</td>
      <td>1.213588e-17</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>436</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,107,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>4.036740e-20</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>437</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,107,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>4.036740e-20</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>438</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,107,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>4.036740e-20</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>439</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,107,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>4.036740e-20</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>440</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,107,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>4.036740e-20</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>441</th>
      <td>acute</td>
      <td>107</td>
      <td>50</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,107,20.0,2014,24277020,50,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.532710</td>
      <td>1.000000e+00</td>
      <td>-0.532710</td>
      <td>4.036740e-20</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>442</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>2.746176e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.041176</td>
      <td>0.389441</td>
      <td>0.041176</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>443</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>2.746176e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.099071</td>
      <td>0.285822</td>
      <td>0.099071</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>444</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>2.746176e-02</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041176</td>
      <td>0.999830</td>
      <td>-0.041176</td>
      <td>0.389441</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>445</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>2.746176e-02</td>
      <td>acute</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>18</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>18</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.057895</td>
      <td>0.354792</td>
      <td>0.057895</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>446</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>2.746176e-02</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.099071</td>
      <td>0.999830</td>
      <td>-0.099071</td>
      <td>0.285822</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>447</th>
      <td>acute</td>
      <td>114</td>
      <td>110</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,110,114,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t</td>
      <td>-0.035088</td>
      <td>1.000000e+00</td>
      <td>-0.035088</td>
      <td>2.746176e-02</td>
      <td>acute</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>19</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>16</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>16</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.057895</td>
      <td>0.999810</td>
      <td>-0.057895</td>
      <td>0.354792</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>448</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>449</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>450</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>451</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10,10.0,100000.0,111.0,2014,24277020,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>452</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,3,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>453</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,3,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>454</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,3,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>455</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,10,100.0,100000.0,111.0,2014,24277020,3,500.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>456</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>457</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>458</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>459</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,12.5,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>460</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,3,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>461</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,3,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>462</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,3,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>463</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,3,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>464</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>465</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>466</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>467</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,15.0,2014,24277020,3,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>468</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,3,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>1.416338e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>469</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,3,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>1.416338e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>470</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,3,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>1.416338e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>471</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,100000.0,111.0,150.0,20,20,2014,24277020,3,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>1.416338e-05</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>472</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,3,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>473</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,3,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>474</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,3,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>475</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,1500.0,2014,24277020,3,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>476</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>477</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>478</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>479</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,10,100000.0,111.0,2014,24277020,250.0,3,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>480</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>481</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>482</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>483</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,20,2014,24277020,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>484</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>485</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>486</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>487</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,12.5,2014,24277020,250.0,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>488</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>489</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>490</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>491</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,20,2014,24277020,25.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>492</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>493</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>494</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>495</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>496</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>497</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>498</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>499</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>500</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>501</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>502</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>503</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>504</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>505</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>506</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>507</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>508</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>509</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>510</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>511</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>512</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>513</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>514</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>515</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,acute,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>516</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,11,110,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.874003</td>
      <td>1.000000e+00</td>
      <td>-0.874003</td>
      <td>2.147316e-10</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>517</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,11,110,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.874003</td>
      <td>1.000000e+00</td>
      <td>-0.874003</td>
      <td>2.147316e-10</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>518</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,11,110,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.874003</td>
      <td>1.000000e+00</td>
      <td>-0.874003</td>
      <td>2.147316e-10</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>519</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>110</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,11,110,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.874003</td>
      <td>1.000000e+00</td>
      <td>-0.874003</td>
      <td>2.147316e-10</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>520</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,107,11,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.909091</td>
      <td>1.000000e+00</td>
      <td>-0.909091</td>
      <td>1.613829e-14</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>521</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,107,11,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.909091</td>
      <td>1.000000e+00</td>
      <td>-0.909091</td>
      <td>1.613829e-14</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>522</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,107,11,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.909091</td>
      <td>1.000000e+00</td>
      <td>-0.909091</td>
      <td>1.613829e-14</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>523</th>
      <td>acute</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,107,11,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.909091</td>
      <td>1.000000e+00</td>
      <td>-0.909091</td>
      <td>1.613829e-14</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>524</th>
      <td>acute</td>
      <td>17</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,15,17,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.117647</td>
      <td>1.000000e+00</td>
      <td>-0.117647</td>
      <td>6.332198e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>85.2 (80.9 to 88.7)</td>
      <td>NaN</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>270</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>253</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.011308</td>
      <td>0.392520</td>
      <td>0.011308</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>525</th>
      <td>acute</td>
      <td>17</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,15,17,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.117647</td>
      <td>1.000000e+00</td>
      <td>-0.117647</td>
      <td>6.332198e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>16</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077540</td>
      <td>0.999830</td>
      <td>-0.077540</td>
      <td>0.319059</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>526</th>
      <td>acute</td>
      <td>17</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,15,17,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.117647</td>
      <td>1.000000e+00</td>
      <td>-0.117647</td>
      <td>6.332198e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>18</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.036364</td>
      <td>0.999800</td>
      <td>-0.036364</td>
      <td>0.410568</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>527</th>
      <td>acute</td>
      <td>17</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>107</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,107,15,17,2.0,20.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,acute,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.117647</td>
      <td>1.000000e+00</td>
      <td>-0.117647</td>
      <td>6.332198e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified clinical cure rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>19</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>19</td>
      <td>antibiotic</td>
      <td>19</td>
      <td>16</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.021531</td>
      <td>0.466658</td>
      <td>0.021531</td>
      <td>0.999810</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>528</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2,2014,24277020,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>1.074867e-01</td>
      <td>0.200000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>529</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2,2014,24277020,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>1.074867e-01</td>
      <td>0.200000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>530</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2,2014,24277020,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>1.074867e-01</td>
      <td>0.200000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>531</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.3,0.3,1.5,1.5,10,10,100000.0,111.0,2,2014,24277020,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>1.074867e-01</td>
      <td>0.200000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>532</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.701387e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>533</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.701387e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>534</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.701387e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>535</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,3,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.701387e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>536</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>537</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>538</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>539</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>540</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>541</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>542</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>543</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>544</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,2014,24277020,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>545</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,2014,24277020,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>546</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,2014,24277020,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>547</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,2014,24277020,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>548</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>549</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>550</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>551</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>552</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,2,20,20,2014,24277020,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>553</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,2,20,20,2014,24277020,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>554</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,2,20,20,2014,24277020,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>555</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,100000.0,111.0,2,20,20,2014,24277020,250.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>556</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>557</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>558</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>559</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>560</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>561</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>562</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>563</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>564</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>565</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>566</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>567</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2014,24277020,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>568</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>569</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>570</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>571</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,2014,24277020,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>572</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>573</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>574</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>575</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>576</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>577</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>578</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>579</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10.0,100000.0,111.0,20,20,2014,24277020,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>580</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,3,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>2.069473e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>581</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,3,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>2.069473e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>582</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,3,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>2.069473e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>583</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,3,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>2.069473e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>584</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,4,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>585</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,4,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>586</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,4,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>587</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,4,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>588</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>589</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>590</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>591</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2014,24277020,3.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>592</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>593</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>594</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>595</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,2014,24277020,30.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>596</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>597</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>598</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>599</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,8,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>600</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>3.752554e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>601</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>3.752554e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>602</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>3.752554e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>603</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100.0,100000.0,111.0,20,20,2014,24277020,250.0,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>3.752554e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>604</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100000.0,111.0,12.5,12.5,2014,24277020,3,4,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>605</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100000.0,111.0,12.5,12.5,2014,24277020,3,4,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>606</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100000.0,111.0,12.5,12.5,2014,24277020,3,4,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>607</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100000.0,111.0,12.5,12.5,2014,24277020,3,4,58.0,62.5,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.883320e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>608</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>609</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>610</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>611</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>612</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>613</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>614</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>615</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2014,24277020,3.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>616</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>617</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>618</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>619</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,2014,24277020,30.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>620</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>621</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>622</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>623</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,62.5,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>624</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>625</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>626</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>627</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,12.5,20,20,2014,24277020,250.0,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>628</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>629</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>630</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>631</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,125.0,125.0,2014,24277020,25.0,25.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>632</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>633</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>634</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>635</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2014,24277020,25.0,3.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>636</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>637</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>638</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>639</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,2014,24277020,25.0,30.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>640</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>641</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>642</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>643</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>644</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>645</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>646</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>647</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,125.0,20,20,2014,24277020,25.0,250.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>648</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,15.0,15.0,2,2014,24277020,3.0,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>649</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,15.0,15.0,2,2014,24277020,3.0,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>650</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,15.0,15.0,2,2014,24277020,3.0,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>651</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,15.0,15.0,2,2014,24277020,3.0,3.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>652</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,2014,24277020,3.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>653</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,2014,24277020,3.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>654</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,2014,24277020,3.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>655</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,2014,24277020,3.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>656</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>657</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>658</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>659</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>660</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,15.0,2,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>661</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,15.0,2,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>662</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,15.0,2,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>663</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,15.0,2,20,20,2014,24277020,250.0,3.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.498430e-06</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>664</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,2014,24277020,30.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>665</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,2014,24277020,30.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>666</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,2014,24277020,30.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>667</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,150.0,150.0,20,2014,24277020,30.0,30.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>668</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>669</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>670</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>671</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>672</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,150.0,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>9.630726e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>673</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,150.0,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>9.630726e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>674</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,150.0,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>9.630726e-05</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>675</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,150.0,20,20,20,2014,24277020,250.0,30.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>9.630726e-05</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>676</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>677</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>678</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>679</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,1500.0,1500.0,2014,24277020,300.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>680</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>681</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>682</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>683</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,1500.0,20,20,2014,24277020,250.0,300.0,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.162239e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>684</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>685</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>686</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>687</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>20</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,100000.0,111.0,20,20,2014,24277020,250.0,250.0,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>8.133573e-05</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>688</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.310960</td>
      <td>4.798047e-02</td>
      <td>0.310960</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>689</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.310960</td>
      <td>4.798047e-02</td>
      <td>0.310960</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>690</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.310960</td>
      <td>4.798047e-02</td>
      <td>0.310960</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>691</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>1</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1,1.0,1.0,100000.0,107,11,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.310960</td>
      <td>4.798047e-02</td>
      <td>0.310960</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>692</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,12,17,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.304013</td>
      <td>1.000000e+00</td>
      <td>-0.304013</td>
      <td>5.828734e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>693</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,12,17,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.304013</td>
      <td>1.000000e+00</td>
      <td>-0.304013</td>
      <td>5.828734e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>694</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,12,17,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.304013</td>
      <td>1.000000e+00</td>
      <td>-0.304013</td>
      <td>5.828734e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>695</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,107,12,17,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.304013</td>
      <td>1.000000e+00</td>
      <td>-0.304013</td>
      <td>5.828734e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>696</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,20.0,2014,24277020,43,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.416313</td>
      <td>1.000000e+00</td>
      <td>-0.416313</td>
      <td>3.872022e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>697</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,20.0,2014,24277020,43,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.416313</td>
      <td>1.000000e+00</td>
      <td>-0.416313</td>
      <td>3.872022e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>698</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,20.0,2014,24277020,43,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.416313</td>
      <td>1.000000e+00</td>
      <td>-0.416313</td>
      <td>3.872022e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>699</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,11,20.0,2014,24277020,43,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.416313</td>
      <td>1.000000e+00</td>
      <td>-0.416313</td>
      <td>3.872022e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>700</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,105,114,12,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215170</td>
      <td>1.877210e-02</td>
      <td>0.215170</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>701</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,105,114,12,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215170</td>
      <td>1.877210e-02</td>
      <td>0.215170</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>702</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,105,114,12,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215170</td>
      <td>1.877210e-02</td>
      <td>0.215170</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>703</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>17</td>
      <td>12</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>10.0,10.0,100000.0,105,114,12,17,2.0,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215170</td>
      <td>1.877210e-02</td>
      <td>0.215170</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>704</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,11,114,2.0,20.0,2014,24277020,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.102871</td>
      <td>1.763802e-01</td>
      <td>0.102871</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>705</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,11,114,2.0,20.0,2014,24277020,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.102871</td>
      <td>1.763802e-01</td>
      <td>0.102871</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>706</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,11,114,2.0,20.0,2014,24277020,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.102871</td>
      <td>1.763802e-01</td>
      <td>0.102871</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>707</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,11,114,2.0,20.0,2014,24277020,70.0,87.0,9,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.102871</td>
      <td>1.763802e-01</td>
      <td>0.102871</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>708</th>
      <td>sustained</td>
      <td>107</td>
      <td>94</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,11,20.0,20.0,2014,24277020,70.0,87.0,9,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.060323</td>
      <td>4.540553e-01</td>
      <td>0.060323</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>no</td>
      <td>302</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>65.6 (60.0 to 70.7)</td>
      <td>Superiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>318</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.032988</td>
      <td>0.255728</td>
      <td>0.032988</td>
      <td>0.996994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>709</th>
      <td>sustained</td>
      <td>107</td>
      <td>94</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,11,20.0,20.0,2014,24277020,70.0,87.0,9,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.060323</td>
      <td>4.540553e-01</td>
      <td>0.060323</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.219251</td>
      <td>0.095646</td>
      <td>0.219251</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>710</th>
      <td>sustained</td>
      <td>107</td>
      <td>94</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,11,20.0,20.0,2014,24277020,70.0,87.0,9,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.060323</td>
      <td>4.540553e-01</td>
      <td>0.060323</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.154545</td>
      <td>0.244436</td>
      <td>0.154545</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>711</th>
      <td>sustained</td>
      <td>107</td>
      <td>94</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>11</td>
      <td>9</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,100000.0,107,11,20.0,20.0,2014,24277020,70.0,87.0,9,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.060323</td>
      <td>4.540553e-01</td>
      <td>0.060323</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>22</td>
      <td>12</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.010101</td>
      <td>0.512835</td>
      <td>0.010101</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>712</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10.0,100000.0,111.0,2,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>713</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10.0,100000.0,111.0,2,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>714</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10.0,100000.0,111.0,2,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>715</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10.0,100000.0,111.0,2,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>716</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10.0,100000.0,111.0,2,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>717</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0.3,1.5,10,10,10.0,100000.0,111.0,2,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>718</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,100.0,100000.0,111.0,2,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>719</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,100.0,100000.0,111.0,2,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>720</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,100.0,100000.0,111.0,2,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>721</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,100.0,100000.0,111.0,2,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>722</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,100.0,100000.0,111.0,2,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>723</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,10,10,100.0,100000.0,111.0,2,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>5.908966e-03</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>724</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>725</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>726</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>727</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>728</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>729</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0.3,1.5,10,10,100000.0,111.0,12.5,2,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>730</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>731</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>732</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>733</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>734</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>735</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,125.0,2,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>736</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>737</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>738</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>739</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>740</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>741</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,15.0,2,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>742</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>743</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>744</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>745</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>746</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>747</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,150.0,2,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>748</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>749</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>750</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>751</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>752</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>753</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,1500.0,2,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>754</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,2,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>755</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,2,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>756</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,2,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>757</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,2,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>758</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,2,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>759</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0.3,1.5,10,10,100000.0,111.0,2,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>760</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10.0,100.0,100000.0,111.0,2014,24277020,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>761</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10.0,100.0,100000.0,111.0,2014,24277020,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>762</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10.0,100.0,100000.0,111.0,2014,24277020,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>763</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10.0,100.0,100000.0,111.0,2014,24277020,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>764</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10.0,100.0,100000.0,111.0,2014,24277020,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>765</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>10,10,10.0,100.0,100000.0,111.0,2014,24277020,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>766</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>767</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>768</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>769</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>770</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>771</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,10.0,100000.0,111.0,12.5,2014,24277020,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>772</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>773</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>774</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>775</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>776</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>777</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,100000.0,111.0,125.0,2014,24277020,25.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>778</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2,2014,24277020,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>779</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2,2014,24277020,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>780</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2,2014,24277020,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>781</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2,2014,24277020,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>782</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2,2014,24277020,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>783</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,10.0,100000.0,111.0,15.0,2,2014,24277020,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>784</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,2014,24277020,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>785</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,2014,24277020,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>786</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,2014,24277020,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>787</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,2014,24277020,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>788</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,2014,24277020,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>789</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,10.0,100000.0,111.0,150.0,20,2014,24277020,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>790</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>791</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>792</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>793</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>794</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>795</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,10.0,100000.0,111.0,1500.0,2014,24277020,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>796</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,2014,24277020,250.0,4,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>797</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,2014,24277020,250.0,4,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>798</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,2014,24277020,250.0,4,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>799</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,2014,24277020,250.0,4,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>800</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,2014,24277020,250.0,4,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>801</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>10.00</td>
      <td>50.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,100000.0,111.0,2014,24277020,250.0,4,4,50.0,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>802</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,4,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>803</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,4,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>804</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,4,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>805</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,4,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>806</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,4,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>807</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>10,10,100.0,100000.0,111.0,12.5,2014,24277020,4,500.0,58.0,62.5,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>808</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>809</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>810</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>811</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>812</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>813</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100.0,100000.0,111.0,125.0,2014,24277020,25.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>814</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2,2014,24277020,3.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.600000</td>
      <td>5.908966e-03</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>815</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2,2014,24277020,3.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.600000</td>
      <td>5.908966e-03</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>816</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2,2014,24277020,3.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.600000</td>
      <td>5.908966e-03</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>817</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2,2014,24277020,3.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.600000</td>
      <td>5.908966e-03</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>818</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2,2014,24277020,3.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.600000</td>
      <td>5.908966e-03</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>819</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100.0,100000.0,111.0,15.0,2,2014,24277020,3.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.600000</td>
      <td>5.908966e-03</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>820</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,2014,24277020,30.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>6.804742e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>821</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,2014,24277020,30.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>6.804742e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>822</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,2014,24277020,30.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>6.804742e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>823</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,2014,24277020,30.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>6.804742e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>824</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,2014,24277020,30.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>6.804742e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>825</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100.0,100000.0,111.0,150.0,20,2014,24277020,30.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>6.804742e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>826</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>827</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>828</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>829</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>830</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>831</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100.0,100000.0,111.0,1500.0,2014,24277020,300.0,500.0,58.0,6,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>832</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,2014,24277020,250.0,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>833</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,2014,24277020,250.0,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>834</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,2014,24277020,250.0,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>835</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,2014,24277020,250.0,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>836</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,2014,24277020,250.0,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>837</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>100.00</td>
      <td>500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100.0,100000.0,111.0,2014,24277020,250.0,4,50.0,500.0,58.0,8,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>838</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>839</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>840</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>841</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>842</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>843</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>844</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>845</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>846</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>847</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>848</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>849</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>850</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,30.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>851</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,30.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>852</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,30.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>853</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,30.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>854</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,30.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>855</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,30.0,4,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>856</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>857</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>858</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>859</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>860</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>861</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,300.0,4,58.0,6,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>862</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>863</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>864</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>865</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>866</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>867</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,4,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>868</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>869</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>870</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>871</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>872</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>873</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>874</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>875</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>876</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>877</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>878</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>879</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>880</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>881</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>882</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>883</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>884</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>885</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>886</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>887</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>888</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>889</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>890</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>891</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>892</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>893</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>894</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>895</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>896</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>897</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,2,20,2014,24277020,3.0,30.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>6.804742e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>898</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>899</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>900</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>901</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>902</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>903</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2,2014,24277020,3.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>904</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2,2014,24277020,250.0,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>905</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2,2014,24277020,250.0,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>906</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2,2014,24277020,250.0,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>907</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2,2014,24277020,250.0,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>908</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2,2014,24277020,250.0,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>909</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2,2014,24277020,250.0,3.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617207e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>910</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>911</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>912</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>913</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>914</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>915</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,20,2014,24277020,30.0,300.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>916</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,2014,24277020,250.0,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>917</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,2014,24277020,250.0,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>918</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,2014,24277020,250.0,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>919</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,2014,24277020,250.0,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>920</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,2014,24277020,250.0,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>921</th>
      <td>sustained</td>
      <td>20</td>
      <td>10</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,20,2014,24277020,250.0,30.0,4,50.0,58.0,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>922</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>923</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>924</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>925</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>926</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>927</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>928</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,105,107,114,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.519183</td>
      <td>1.000000e+00</td>
      <td>-0.519183</td>
      <td>1.899613e-17</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>929</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,105,107,114,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.519183</td>
      <td>1.000000e+00</td>
      <td>-0.519183</td>
      <td>1.899613e-17</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>930</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,105,107,114,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.519183</td>
      <td>1.000000e+00</td>
      <td>-0.519183</td>
      <td>1.899613e-17</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>931</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,105,107,114,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.519183</td>
      <td>1.000000e+00</td>
      <td>-0.519183</td>
      <td>1.899613e-17</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>932</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,105,107,114,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.519183</td>
      <td>1.000000e+00</td>
      <td>-0.519183</td>
      <td>1.899613e-17</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>933</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1.0,10.0,100000.0,105,107,114,2.0,2014,24277020,43,70.0,87.0,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.519183</td>
      <td>1.000000e+00</td>
      <td>-0.519183</td>
      <td>1.899613e-17</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>934</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,20.0,2014,24277020,43,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.476636</td>
      <td>1.000000e+00</td>
      <td>-0.476636</td>
      <td>6.450359e-14</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>935</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,20.0,2014,24277020,43,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.476636</td>
      <td>1.000000e+00</td>
      <td>-0.476636</td>
      <td>6.450359e-14</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>936</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,20.0,2014,24277020,43,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.476636</td>
      <td>1.000000e+00</td>
      <td>-0.476636</td>
      <td>6.450359e-14</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>937</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,20.0,2014,24277020,43,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.476636</td>
      <td>1.000000e+00</td>
      <td>-0.476636</td>
      <td>6.450359e-14</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>938</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,20.0,2014,24277020,43,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.476636</td>
      <td>1.000000e+00</td>
      <td>-0.476636</td>
      <td>6.450359e-14</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>939</th>
      <td>sustained</td>
      <td>107</td>
      <td>43</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1.0,100.0,100000.0,107,107,20.0,2014,24277020,43,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.476636</td>
      <td>1.000000e+00</td>
      <td>-0.476636</td>
      <td>6.450359e-14</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>940</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,107,114,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.042548</td>
      <td>1.693235e-01</td>
      <td>0.042548</td>
      <td>9.999994e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>0.064706</td>
      <td>0.389519</td>
      <td>0.064706</td>
      <td>0.999830</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>941</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,107,114,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.042548</td>
      <td>1.693235e-01</td>
      <td>0.042548</td>
      <td>9.999994e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>17</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>13</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>13</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.209150</td>
      <td>0.124657</td>
      <td>0.209150</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>942</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,107,114,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.042548</td>
      <td>1.693235e-01</td>
      <td>0.042548</td>
      <td>9.999994e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.064706</td>
      <td>0.999830</td>
      <td>-0.064706</td>
      <td>0.389519</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>943</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,107,114,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.042548</td>
      <td>1.693235e-01</td>
      <td>0.042548</td>
      <td>9.999994e-01</td>
      <td>sustained</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>500</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>20</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>0.144444</td>
      <td>0.284700</td>
      <td>0.144444</td>
      <td>0.999820</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>944</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,107,114,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.042548</td>
      <td>1.693235e-01</td>
      <td>0.042548</td>
      <td>9.999994e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.209150</td>
      <td>1.000000</td>
      <td>-0.209150</td>
      <td>0.124657</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>945</th>
      <td>sustained</td>
      <td>114</td>
      <td>105</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,105,107,114,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.042548</td>
      <td>1.693235e-01</td>
      <td>0.042548</td>
      <td>9.999994e-01</td>
      <td>sustained</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>1000</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Cadazolid</td>
      <td>yes</td>
      <td>18</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.144444</td>
      <td>0.999820</td>
      <td>-0.144444</td>
      <td>0.284700</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>946</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0,0.3,1.5,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>947</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0,0.3,1.5,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>948</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0,0.3,1.5,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>949</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>10.00</td>
      <td>50.0</td>
      <td>0,0.3,1.5,10,10,10.0,100000.0,111.0,2014,24277020,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>950</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0.3,1.5,10,10,100.0,100000.0,111.0,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.058578e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>951</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0.3,1.5,10,10,100.0,100000.0,111.0,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.058578e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>952</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0.3,1.5,10,10,100.0,100000.0,111.0,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.058578e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>953</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0.3,1.5,10,10,100.0,100000.0,111.0,2014,24277020,500.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.058578e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>954</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>955</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>956</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>957</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>12.50</td>
      <td>62.5</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,12.5,2014,24277020,4,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>958</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,125.0,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>959</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,125.0,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>960</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,125.0,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>961</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,125.0,2014,24277020,25.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>962</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.074867e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>963</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.074867e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>964</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.074867e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>965</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,15.0,2,2014,24277020,3.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.074867e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>966</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,150.0,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.419062e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>967</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,150.0,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.419062e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>968</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,150.0,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.419062e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>969</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,150.0,20,2014,24277020,30.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.419062e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>970</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>971</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>972</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>973</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,1500.0,2014,24277020,300.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>1.758278e-03</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>974</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>975</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>976</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>977</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0.3,1.5,10,10,100000.0,111.0,2014,24277020,250.0,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>978</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,3,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>979</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,3,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>980</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,3,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>981</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,100000.0,111.0,12.5,125.0,2014,24277020,25.0,3,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>982</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.701387e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>983</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.701387e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>984</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.701387e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>985</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,12.5,15.0,2,2014,24277020,3,3.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.701387e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>986</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,3,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.822590e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>987</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,3,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.822590e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>988</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,3,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.822590e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>989</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,12.5,150.0,20,2014,24277020,3,30.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>1.000000e+00</td>
      <td>-0.200000</td>
      <td>1.822590e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>990</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,3,300.0,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>991</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,3,300.0,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>992</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,3,300.0,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>993</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,12.5,1500.0,2014,24277020,3,300.0,58.0,6,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>1.316738e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>994</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>995</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>996</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>997</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>12.50</td>
      <td>62.50</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,12.5,2014,24277020,250.0,3,4,50.0,58.0,62.5,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>998</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>999</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1000</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1001</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>2</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10,10,100000.0,111.0,125.0,15.0,2,2014,24277020,25.0,3.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1002</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1003</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1004</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1005</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,125.0,150.0,20,2014,24277020,25.0,30.0,4,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.925093e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1006</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1007</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1008</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1009</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,125.0,1500.0,2014,24277020,25.0,300.0,4,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617373e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1010</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1011</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1012</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1013</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,125.0,2014,24277020,25.0,250.0,4,4,50.0,58.0,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1014</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,2014,24277020,3.0,30.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1015</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,2014,24277020,3.0,30.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1016</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,2014,24277020,3.0,30.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1017</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>20</td>
      <td>10</td>
      <td>30.00</td>
      <td>150.0</td>
      <td>10,10,100000.0,111.0,15.0,150.0,20,2014,24277020,3.0,30.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.100000</td>
      <td>3.925093e-01</td>
      <td>0.100000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1018</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1019</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1020</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1021</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,15.0,1500.0,2014,24277020,3.0,300.0,58.0,6,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1022</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1023</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1024</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1025</th>
      <td>sustained</td>
      <td>10</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,15.0,2014,24277020,250.0,3.0,4,50.0,58.0,6,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617373e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1026</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1027</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1028</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1029</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>6</td>
      <td>300.00</td>
      <td>1500.0</td>
      <td>10,10,100000.0,111.0,150.0,1500.0,2014,24277020,30.0,300.0,58.0,6,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.200000</td>
      <td>2.617207e-01</td>
      <td>0.200000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1030</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1031</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1032</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1033</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>30.00</td>
      <td>150.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,150.0,2014,24277020,250.0,30.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1034</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1035</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1036</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1037</th>
      <td>sustained</td>
      <td>10</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>58.0</td>
      <td>111.0</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>300.00</td>
      <td>1500.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,100000.0,111.0,1500.0,2014,24277020,250.0,300.0,4,50.0,58.0,8,87.0,CFU,Cadazolid,Golden Syrian,M,VPI 10463,clindamycin+challenge,cumulative mortality,hamster,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>4.743900e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1038</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,105,11,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.830144</td>
      <td>1.000000e+00</td>
      <td>-0.830144</td>
      <td>4.544677e-07</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1039</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,105,11,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.830144</td>
      <td>1.000000e+00</td>
      <td>-0.830144</td>
      <td>4.544677e-07</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1040</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,105,11,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.830144</td>
      <td>1.000000e+00</td>
      <td>-0.830144</td>
      <td>4.544677e-07</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1041</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>114</td>
      <td>105</td>
      <td>2.00</td>
      <td>10.0</td>
      <td>0.2,1,1.0,10.0,100000.0,105,11,114,2.0,2014,24277020,70.0,87.0,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.830144</td>
      <td>1.000000e+00</td>
      <td>-0.830144</td>
      <td>4.544677e-07</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1042</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,11,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.787596</td>
      <td>1.000000e+00</td>
      <td>-0.787596</td>
      <td>1.098809e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1043</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,11,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.787596</td>
      <td>1.000000e+00</td>
      <td>-0.787596</td>
      <td>1.098809e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1044</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,11,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.787596</td>
      <td>1.000000e+00</td>
      <td>-0.787596</td>
      <td>1.098809e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1045</th>
      <td>sustained</td>
      <td>11</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0.2,1,1.0,100.0,100000.0,107,11,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.787596</td>
      <td>1.000000e+00</td>
      <td>-0.787596</td>
      <td>1.098809e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1046</th>
      <td>sustained</td>
      <td>17</td>
      <td>12</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,12,17,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.172622</td>
      <td>1.000000e+00</td>
      <td>-0.172622</td>
      <td>6.133929e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>318</td>
      <td>therapeutic</td>
      <td>Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical \nCure and no recurrence. SCR is the percentage of subjects with Sustained\n Cure. The main analysis is performed on the modified intent-to-treat \nset (mITT).</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>62.3 (56.8 to 67.4)</td>
      <td>Inferiority</td>
      <td>Wilson's score method</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>198</td>
      <td>antibiotic</td>
      <td>302</td>
      <td>198</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.032988</td>
      <td>0.996994</td>
      <td>-0.032988</td>
      <td>0.255728</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1047</th>
      <td>sustained</td>
      <td>17</td>
      <td>12</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,12,17,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.172622</td>
      <td>1.000000e+00</td>
      <td>-0.172622</td>
      <td>6.133929e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>17</td>
      <td>13</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.219251</td>
      <td>1.000000</td>
      <td>-0.219251</td>
      <td>0.095646</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1048</th>
      <td>sustained</td>
      <td>17</td>
      <td>12</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,12,17,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.172622</td>
      <td>1.000000e+00</td>
      <td>-0.172622</td>
      <td>6.133929e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>20</td>
      <td>14</td>
      <td>1000.0</td>
      <td>10000.0</td>
      <td>-0.154545</td>
      <td>1.000000</td>
      <td>-0.154545</td>
      <td>0.244436</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1049</th>
      <td>sustained</td>
      <td>17</td>
      <td>12</td>
      <td>positive</td>
      <td>NaN</td>
      <td>C57BL/6</td>
      <td>F</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>70.0</td>
      <td>NaN</td>
      <td>100000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>Cadazolid</td>
      <td>therapeutic</td>
      <td>107</td>
      <td>94</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10.0,100.0,100000.0,107,12,17,2.0,20.0,2014,24277020,70.0,87.0,94,C57BL/6,CFU,Cadazolid,F,VPI 10463,cumulative mortality,kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge,mouse,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.172622</td>
      <td>1.000000e+00</td>
      <td>-0.172622</td>
      <td>6.133929e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>22</td>
      <td>therapeutic</td>
      <td>Modified sustained clinical response rate</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>18</td>
      <td>10</td>
      <td>2000.0</td>
      <td>20000.0</td>
      <td>-0.010101</td>
      <td>0.999820</td>
      <td>-0.010101</td>
      <td>0.512835</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1050</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1051</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1052</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1053</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1054</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1055</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1056</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1057</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1058</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1059</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1060</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1061</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1062</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1063</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1064</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1065</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1066</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1067</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1068</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1069</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1070</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1071</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1072</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1073</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1074</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1075</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1076</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1077</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1078</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1079</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1080</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1081</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1082</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1083</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1084</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1085</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1086</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1087</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1088</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1089</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1090</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1091</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1092</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>6.389618e-03</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1093</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>6.389618e-03</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1094</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>6.389618e-03</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1095</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>6.389618e-03</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1096</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>6.389618e-03</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1097</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>6.389618e-03</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1098</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1099</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1100</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1101</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1102</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1103</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1104</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1105</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1106</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1107</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1108</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1109</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1110</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1111</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1112</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1113</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1114</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1115</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1116</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1117</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1118</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1119</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1120</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1121</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1122</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1123</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1124</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1125</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1126</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1127</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1128</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.03,0.15,100.0,2,2009155,2018,27.0,29439962,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>7.299805e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1129</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.03,0.15,100.0,2,2009155,2018,27.0,29439962,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>7.299805e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1130</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.03,0.15,100.0,2,2009155,2018,27.0,29439962,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>7.299805e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1131</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.03,0.15,100.0,2,2009155,2018,27.0,29439962,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>7.299805e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1132</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.03,0.15,100.0,2,2009155,2018,27.0,29439962,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>7.299805e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1133</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.03,0.15,100.0,2,2009155,2018,27.0,29439962,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>7.299805e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1134</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,100.0,2009155,2018,27.0,29439962,3,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.333333</td>
      <td>1.000000e+00</td>
      <td>-0.333333</td>
      <td>1.514493e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1135</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,100.0,2009155,2018,27.0,29439962,3,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.333333</td>
      <td>1.000000e+00</td>
      <td>-0.333333</td>
      <td>1.514493e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1136</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,100.0,2009155,2018,27.0,29439962,3,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.333333</td>
      <td>1.000000e+00</td>
      <td>-0.333333</td>
      <td>1.514493e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1137</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,100.0,2009155,2018,27.0,29439962,3,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.333333</td>
      <td>1.000000e+00</td>
      <td>-0.333333</td>
      <td>1.514493e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1138</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,100.0,2009155,2018,27.0,29439962,3,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.333333</td>
      <td>1.000000e+00</td>
      <td>-0.333333</td>
      <td>1.514493e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1139</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0.3,1.5,100.0,2009155,2018,27.0,29439962,3,30000.0,5,500.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.333333</td>
      <td>1.000000e+00</td>
      <td>-0.333333</td>
      <td>1.514493e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1140</th>
      <td>acute</td>
      <td>6</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>100.0,15.0,2009155,2018,27.0,29439962,3.0,30000.0,5,500.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.166667</td>
      <td>2.590336e-01</td>
      <td>0.166667</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1141</th>
      <td>acute</td>
      <td>6</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>100.0,15.0,2009155,2018,27.0,29439962,3.0,30000.0,5,500.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.166667</td>
      <td>2.590336e-01</td>
      <td>0.166667</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1142</th>
      <td>acute</td>
      <td>6</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>100.0,15.0,2009155,2018,27.0,29439962,3.0,30000.0,5,500.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.166667</td>
      <td>2.590336e-01</td>
      <td>0.166667</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1143</th>
      <td>acute</td>
      <td>6</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>100.0,15.0,2009155,2018,27.0,29439962,3.0,30000.0,5,500.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.166667</td>
      <td>2.590336e-01</td>
      <td>0.166667</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1144</th>
      <td>acute</td>
      <td>6</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>100.0,15.0,2009155,2018,27.0,29439962,3.0,30000.0,5,500.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.166667</td>
      <td>2.590336e-01</td>
      <td>0.166667</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1145</th>
      <td>acute</td>
      <td>6</td>
      <td>6</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>5</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>100.0,15.0,2009155,2018,27.0,29439962,3.0,30000.0,5,500.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.166667</td>
      <td>2.590336e-01</td>
      <td>0.166667</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1146</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1147</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1148</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1149</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1150</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1151</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1152</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1153</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1154</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1155</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1156</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1157</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1158</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1159</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1160</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1161</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1162</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1163</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1164</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1165</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1166</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1167</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1168</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1169</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,10,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1170</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1171</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1172</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1173</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1174</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1175</th>
      <td>acute</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,10,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1176</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1177</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1178</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1179</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1180</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1181</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1182</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1183</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1184</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1185</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1186</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1187</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>10,10,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1188</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1189</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1190</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1191</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1192</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1193</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1194</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1195</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1196</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1197</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1198</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1199</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1200</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1201</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1202</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1203</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1204</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1205</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1206</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1207</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1208</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1209</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1210</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1211</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1212</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,12.0,2015,225.0,25.0,250.0,25652749,5.0,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1213</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,12.0,2015,225.0,25.0,250.0,25652749,5.0,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1214</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,12.0,2015,225.0,25.0,250.0,25652749,5.0,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1215</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,12.0,2015,225.0,25.0,250.0,25652749,5.0,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1216</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,12.0,2015,225.0,25.0,250.0,25652749,5.0,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1217</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,12.0,2015,225.0,25.0,250.0,25652749,5.0,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1218</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1219</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1220</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1221</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1222</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1223</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1224</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.03,0.15,0.3,1.5,2,2009155,2018,27.0,29439962,3,30000.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.166667</td>
      <td>9.999400e-01</td>
      <td>-0.166667</td>
      <td>3.872070e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1225</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.03,0.15,0.3,1.5,2,2009155,2018,27.0,29439962,3,30000.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.166667</td>
      <td>9.999400e-01</td>
      <td>-0.166667</td>
      <td>3.872070e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1226</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.03,0.15,0.3,1.5,2,2009155,2018,27.0,29439962,3,30000.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.166667</td>
      <td>9.999400e-01</td>
      <td>-0.166667</td>
      <td>3.872070e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1227</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.03,0.15,0.3,1.5,2,2009155,2018,27.0,29439962,3,30000.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.166667</td>
      <td>9.999400e-01</td>
      <td>-0.166667</td>
      <td>3.872070e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1228</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.03,0.15,0.3,1.5,2,2009155,2018,27.0,29439962,3,30000.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.166667</td>
      <td>9.999400e-01</td>
      <td>-0.166667</td>
      <td>3.872070e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1229</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0.03,0.15,0.3,1.5,2,2009155,2018,27.0,29439962,3,30000.0,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.166667</td>
      <td>9.999400e-01</td>
      <td>-0.166667</td>
      <td>3.872070e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1230</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.03,0.15,15.0,2,2009155,2018,27.0,29439962,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.666667</td>
      <td>1.000000e+00</td>
      <td>-0.666667</td>
      <td>1.050317e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1231</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.03,0.15,15.0,2,2009155,2018,27.0,29439962,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.666667</td>
      <td>1.000000e+00</td>
      <td>-0.666667</td>
      <td>1.050317e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1232</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.03,0.15,15.0,2,2009155,2018,27.0,29439962,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.666667</td>
      <td>1.000000e+00</td>
      <td>-0.666667</td>
      <td>1.050317e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1233</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.03,0.15,15.0,2,2009155,2018,27.0,29439962,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.666667</td>
      <td>1.000000e+00</td>
      <td>-0.666667</td>
      <td>1.050317e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1234</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.03,0.15,15.0,2,2009155,2018,27.0,29439962,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.666667</td>
      <td>1.000000e+00</td>
      <td>-0.666667</td>
      <td>1.050317e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1235</th>
      <td>acute</td>
      <td>6</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.03,0.15,15.0,2,2009155,2018,27.0,29439962,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.666667</td>
      <td>1.000000e+00</td>
      <td>-0.666667</td>
      <td>1.050317e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1236</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,15.0,2009155,2018,27.0,29439962,3,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>3.378827e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1237</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,15.0,2009155,2018,27.0,29439962,3,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>3.378827e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1238</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,15.0,2009155,2018,27.0,29439962,3,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>3.378827e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1239</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,15.0,2009155,2018,27.0,29439962,3,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>3.378827e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1240</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,15.0,2009155,2018,27.0,29439962,3,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>3.378827e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1241</th>
      <td>acute</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.30</td>
      <td>1.50</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>6</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0.3,1.5,15.0,2009155,2018,27.0,29439962,3,3.0,30000.0,6,6,6,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>3.378827e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1242</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>1</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>1,1.0,1.0,10.0,2.0,2009155,2018,27.0,29439962,40000.0,5,5,5,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.800000</td>
      <td>1.074219e-02</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1243</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>1</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>1,1.0,1.0,10.0,2.0,2009155,2018,27.0,29439962,40000.0,5,5,5,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.800000</td>
      <td>1.074219e-02</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1244</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>1</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>1,1.0,1.0,10.0,2.0,2009155,2018,27.0,29439962,40000.0,5,5,5,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.800000</td>
      <td>1.074219e-02</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1245</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>1</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>1,1.0,1.0,10.0,2.0,2009155,2018,27.0,29439962,40000.0,5,5,5,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.800000</td>
      <td>1.074219e-02</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1246</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>1</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>1,1.0,1.0,10.0,2.0,2009155,2018,27.0,29439962,40000.0,5,5,5,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.800000</td>
      <td>1.074219e-02</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1247</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>1</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>1,1.0,1.0,10.0,2.0,2009155,2018,27.0,29439962,40000.0,5,5,5,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.800000</td>
      <td>1.074219e-02</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1248</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1249</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1250</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1251</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1252</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1253</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1254</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1255</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1256</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1257</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1258</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1259</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1260</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1261</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1262</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1263</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1264</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1265</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,10,1000000.0,2021,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1266</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1267</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1268</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1269</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1270</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1271</th>
      <td>acute</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1272</th>
      <td>acute</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1273</th>
      <td>acute</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1274</th>
      <td>acute</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1275</th>
      <td>acute</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1276</th>
      <td>acute</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1277</th>
      <td>acute</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,acute,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1278</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1279</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1280</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1281</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1282</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1283</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,5.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1284</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1285</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1286</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1287</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1288</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1289</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1290</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>95</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>95</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>87</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.043091</td>
      <td>0.272350</td>
      <td>0.043091</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1291</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>3</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>8</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.145833</td>
      <td>1.000000</td>
      <td>-0.145833</td>
      <td>0.191477</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1292</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>44</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>70.5 (54.6 to 83.2)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>31</td>
      <td>antibiotic</td>
      <td>98</td>
      <td>76</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.070965</td>
      <td>1.000000</td>
      <td>-0.070965</td>
      <td>0.247704</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1293</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>9</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.250000</td>
      <td>1.000000</td>
      <td>-0.250000</td>
      <td>0.102258</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1294</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>125 mg QID for 10 days</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>5</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>5</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>5</td>
      <td>antibiotic</td>
      <td>7</td>
      <td>4</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.428571</td>
      <td>0.071994</td>
      <td>0.428571</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1295</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,BI1,Golden Syrian,SPF,acute,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>147</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>147</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>138</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>0.041568</td>
      <td>0.267029</td>
      <td>0.041568</td>
      <td>0.998235</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1296</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1297</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1298</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1299</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.04</td>
      <td>0.2</td>
      <td>0,0,0.04,0.04,0.2,0.2,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1300</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1301</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1302</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1303</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1304</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1305</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1306</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1307</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1308</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1309</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1310</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1311</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1312</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1313</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1314</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1315</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.2,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1316</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1317</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1318</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1319</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,33495229,39.0,5,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>6.389618e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1320</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1321</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1322</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1323</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1324</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1325</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1326</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1327</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>5</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5,5.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.200000</td>
      <td>9.999000e-01</td>
      <td>-0.200000</td>
      <td>2.617372e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1328</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1329</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1330</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1331</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1332</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,9,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1333</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,9,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1334</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,9,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1335</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,1000000.0,2021,25.0,25.0,33495229,39.0,5.0,5.0,87.0,9,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1336</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1337</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1338</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1339</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1340</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,0,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1341</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,0,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1342</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,0,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1343</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,0,10,10,100.0,100.0,12.0,20.0,20.0,2015,225.0,25652749,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1344</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>1,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.800000</td>
      <td>2.012253e-04</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1345</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>1,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.800000</td>
      <td>2.012253e-04</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1346</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>1,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.800000</td>
      <td>2.012253e-04</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1347</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>1</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>1,10,10,10.0,100.0,2.0,20.0,2015,225.0,25652749,27.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.800000</td>
      <td>2.012253e-04</td>
      <td>0.800000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1348</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,10.0,100.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>7.236046e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1349</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,10.0,100.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>7.236046e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1350</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,10.0,100.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>7.236046e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1351</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,10.0,100.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.400000</td>
      <td>7.236046e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1352</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0,1.0,1.0,100.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1353</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0,1.0,1.0,100.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1354</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0,1.0,1.0,100.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1355</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,0,1.0,1.0,100.0,2009155,2018,27.0,29439962,40000.0,5,500.0,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1356</th>
      <td>sustained</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,100.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,500.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>3.378827e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1357</th>
      <td>sustained</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,100.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,500.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>3.378827e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1358</th>
      <td>sustained</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,100.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,500.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>3.378827e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1359</th>
      <td>sustained</td>
      <td>6</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>3.00</td>
      <td>15.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>0</td>
      <td>100.00</td>
      <td>500.0</td>
      <td>0,100.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,500.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.500000</td>
      <td>3.378827e-02</td>
      <td>0.500000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1360</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1361</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1362</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1363</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1364</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1365</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0,0.04,0.2,0.2,1.0,10,10,1000000.0,2021,33495229,39.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1366</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1367</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1368</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1369</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1370</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1371</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1372</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1373</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1374</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1375</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1376</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1377</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.04,0.2,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1378</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1379</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1380</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1381</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1382</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1383</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1384</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1385</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1386</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1387</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1388</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1389</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1390</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1391</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1392</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1393</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1394</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1395</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,3,33495229,39.0,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t</td>
      <td>-0.600000</td>
      <td>1.000000e+00</td>
      <td>-0.600000</td>
      <td>3.977776e-03</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1396</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1397</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1398</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1399</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1400</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1401</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>0,10,10,10.0,100.0,12.0,2.0,20.0,2015,225.0,25652749,3,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1402</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,3,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1403</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,3,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1404</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,3,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1405</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,3,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1406</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,3,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1407</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,12.0,2.0,2015,225.0,25.0,25652749,3,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999000e-01</td>
      <td>-0.100000</td>
      <td>3.883320e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1408</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,3,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1409</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,3,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1410</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,3,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1411</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,3,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1412</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,3,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1413</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,3,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.300000</td>
      <td>4.379395e-02</td>
      <td>0.300000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1414</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1415</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1416</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1417</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1418</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1419</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1420</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1421</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1422</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1423</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1424</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1425</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1426</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,12.0,2015,225.0,25.0,250.0,25652749,4,5.0,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>2.109528e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1427</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,12.0,2015,225.0,25.0,250.0,25652749,4,5.0,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>2.109528e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1428</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,12.0,2015,225.0,25.0,250.0,25652749,4,5.0,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>2.109528e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1429</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,12.0,2015,225.0,25.0,250.0,25652749,4,5.0,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>2.109528e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1430</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,12.0,2015,225.0,25.0,250.0,25652749,4,5.0,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>2.109528e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1431</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,12.0,2015,225.0,25.0,250.0,25652749,4,5.0,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>2.109528e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1432</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,9,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1433</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,9,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1434</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,9,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1435</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,9,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1436</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,9,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1437</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10.0,2.0,2015,225.0,25.0,25652749,27.0,5.0,9,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1438</th>
      <td>sustained</td>
      <td>6</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>1</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.03,0.15,0.3,1,1.5,2009155,2018,27.0,29439962,30000.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.166667</td>
      <td>1.000000e+00</td>
      <td>-0.166667</td>
      <td>2.590336e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1439</th>
      <td>sustained</td>
      <td>6</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>1</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.03,0.15,0.3,1,1.5,2009155,2018,27.0,29439962,30000.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.166667</td>
      <td>1.000000e+00</td>
      <td>-0.166667</td>
      <td>2.590336e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1440</th>
      <td>sustained</td>
      <td>6</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>1</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.03,0.15,0.3,1,1.5,2009155,2018,27.0,29439962,30000.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.166667</td>
      <td>1.000000e+00</td>
      <td>-0.166667</td>
      <td>2.590336e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1441</th>
      <td>sustained</td>
      <td>6</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>1</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.03,0.15,0.3,1,1.5,2009155,2018,27.0,29439962,30000.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.166667</td>
      <td>1.000000e+00</td>
      <td>-0.166667</td>
      <td>2.590336e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1442</th>
      <td>sustained</td>
      <td>6</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>1</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.03,0.15,0.3,1,1.5,2009155,2018,27.0,29439962,30000.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.166667</td>
      <td>1.000000e+00</td>
      <td>-0.166667</td>
      <td>2.590336e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1443</th>
      <td>sustained</td>
      <td>6</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>30000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.03</td>
      <td>0.15</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>1</td>
      <td>0.30</td>
      <td>1.5</td>
      <td>0,0.03,0.15,0.3,1,1.5,2009155,2018,27.0,29439962,30000.0,6,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.166667</td>
      <td>1.000000e+00</td>
      <td>-0.166667</td>
      <td>2.590336e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1444</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>0,1.0,1.0,10.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,5,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>9.368845e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1445</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>0,1.0,1.0,10.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,5,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>9.368845e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1446</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>0,1.0,1.0,10.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,5,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>9.368845e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1447</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>0,1.0,1.0,10.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,5,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>9.368845e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1448</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>0,1.0,1.0,10.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,5,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>9.368845e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1449</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>1.0</td>
      <td>0,1.0,1.0,10.0,2,2.0,2009155,2018,27.0,29439962,40000.0,5,5,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.400000</td>
      <td>9.368845e-02</td>
      <td>0.400000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1450</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10.0,15.0,2,2.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999500e-01</td>
      <td>-0.100000</td>
      <td>4.429594e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1451</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10.0,15.0,2,2.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999500e-01</td>
      <td>-0.100000</td>
      <td>4.429594e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1452</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10.0,15.0,2,2.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999500e-01</td>
      <td>-0.100000</td>
      <td>4.429594e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1453</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10.0,15.0,2,2.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999500e-01</td>
      <td>-0.100000</td>
      <td>4.429594e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1454</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10.0,15.0,2,2.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999500e-01</td>
      <td>-0.100000</td>
      <td>4.429594e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1455</th>
      <td>sustained</td>
      <td>5</td>
      <td>2</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>10.0,15.0,2,2.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>9.999500e-01</td>
      <td>-0.100000</td>
      <td>4.429594e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1456</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,1.0,1.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.854040e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1457</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,1.0,1.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.854040e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1458</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,1.0,1.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.854040e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1459</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,1.0,1.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.854040e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1460</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,1.0,1.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.854040e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1461</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>2009155</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>40000.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>1.00</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>6</td>
      <td>3</td>
      <td>3.00</td>
      <td>15.0</td>
      <td>0,1.0,1.0,15.0,2009155,2018,27.0,29439962,3,3.0,40000.0,5,6,Golden Syrian,M,clindamycin+challenge,cumulative mortality,fidaxomicin,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>4.854040e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1462</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1463</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1464</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1465</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.04</td>
      <td>0.20</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.04,0.2,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1466</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1467</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1468</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1469</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,10,10,1000000.0,2021,3,33495229,39.0,5.0,87.0,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.300000</td>
      <td>1.000000e+00</td>
      <td>-0.300000</td>
      <td>4.379395e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1470</th>
      <td>sustained</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>3.115481e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1471</th>
      <td>sustained</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>3.115481e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1472</th>
      <td>sustained</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>3.115481e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1473</th>
      <td>sustained</td>
      <td>10</td>
      <td>5</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>survival</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>39.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,10,10,1000000.0,2021,25.0,33495229,39.0,5,5.0,5.0,87.0,9,CFU,Golden Syrian,M,SPF,VPI 10463,challenge+clindamycin,fidaxomicin,hamster,nan,nan,positive,survival,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>3.115481e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1474</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1475</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1476</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1477</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,25.0,25652749,4,5.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1478</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1479</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1480</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1481</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1482</th>
      <td>sustained</td>
      <td>10</td>
      <td>1</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>2.012253e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1483</th>
      <td>sustained</td>
      <td>10</td>
      <td>1</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>2.012253e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1484</th>
      <td>sustained</td>
      <td>10</td>
      <td>1</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>2.012253e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1485</th>
      <td>sustained</td>
      <td>10</td>
      <td>1</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,10,10,100.0,20.0,2015,225.0,25.0,25652749,27.0,5.0,9,BI1,Golden Syrian,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>2.012253e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1486</th>
      <td>sustained</td>
      <td>10</td>
      <td>2</td>
      <td>positive</td>
      <td>SPF</td>
      <td>C57BL/6</td>
      <td>NaN</td>
      <td>mouse</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>56.0</td>
      <td>NaN</td>
      <td>1000000.0</td>
      <td>CFU</td>
      <td>vegetative</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>actoxumab/bezlotoxumab</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>50.00</td>
      <td>100.0</td>
      <td>10,10,100.0,100.0,1000000.0,2,20.0,2016,27527088,50.0,56.0,87.0,9,C57BL/6,CFU,SPF,VPI 10463,actoxumab/bezlotoxumab,cefoperazone + clindamycin + challenge,cumulative mortality,mouse,nan,nan,p,positive,sustained,t,vancomycin,vegetative</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>1.288414e-03</td>
      <td>sustained</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>27.6</td>
      <td>NaN</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>109</td>
      <td>antibody</td>
      <td>383</td>
      <td>60</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>0.119291</td>
      <td>1.000000</td>
      <td>0.119291</td>
      <td>0.000027</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1487</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>680.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>actoxumab/bezlotoxumab</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>50.00</td>
      <td>200.0</td>
      <td>0,10,10,100.0,12.0,20.0,200.0,2016,27527088,4,50.0,630,680.0,CFU,Golden Syrian,SPF,actoxumab/bezlotoxumab,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,p,positive,spores,sustained,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>2.109528e-02</td>
      <td>sustained</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>395</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>27.6</td>
      <td>NaN</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>109</td>
      <td>antibody</td>
      <td>383</td>
      <td>60</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>0.119291</td>
      <td>1.000000</td>
      <td>0.119291</td>
      <td>0.000027</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1488</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.030303</td>
      <td>0.294131</td>
      <td>0.030303</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1489</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.028268</td>
      <td>0.999341</td>
      <td>-0.028268</td>
      <td>0.345334</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1490</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>79.0 (73.9 to 83.2)</td>
      <td>Non-Inferiority</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>229</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>234</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.046059</td>
      <td>1.000000</td>
      <td>-0.046059</td>
      <td>0.101123</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1491</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.4 (78.7 to 87.2)</td>
      <td>Non-Inferiority</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>237</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>239</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.013086</td>
      <td>0.385580</td>
      <td>0.013086</td>
      <td>0.997162</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1492</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.030303</td>
      <td>0.294131</td>
      <td>0.030303</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1493</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.028268</td>
      <td>0.999341</td>
      <td>-0.028268</td>
      <td>0.345334</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1494</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>79.0 (73.9 to 83.2)</td>
      <td>Non-Inferiority</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>229</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>234</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.046059</td>
      <td>1.000000</td>
      <td>-0.046059</td>
      <td>0.101123</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1495</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.124042e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.4 (78.7 to 87.2)</td>
      <td>Non-Inferiority</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>237</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>239</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.013086</td>
      <td>0.385580</td>
      <td>0.013086</td>
      <td>0.997162</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1496</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.929379e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.030303</td>
      <td>0.294131</td>
      <td>0.030303</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1497</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.929379e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.028268</td>
      <td>0.999341</td>
      <td>-0.028268</td>
      <td>0.345334</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1498</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.929379e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>79.0 (73.9 to 83.2)</td>
      <td>Non-Inferiority</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>229</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>234</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.046059</td>
      <td>1.000000</td>
      <td>-0.046059</td>
      <td>0.101123</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1499</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.929379e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.4 (78.7 to 87.2)</td>
      <td>Non-Inferiority</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>237</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>239</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.013086</td>
      <td>0.385580</td>
      <td>0.013086</td>
      <td>0.997162</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1500</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.030303</td>
      <td>0.294131</td>
      <td>0.030303</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1501</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.028268</td>
      <td>0.999341</td>
      <td>-0.028268</td>
      <td>0.345334</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1502</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>79.0 (73.9 to 83.2)</td>
      <td>Non-Inferiority</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>229</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>234</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.046059</td>
      <td>1.000000</td>
      <td>-0.046059</td>
      <td>0.101123</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1503</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>24</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.4 (78.7 to 87.2)</td>
      <td>Non-Inferiority</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>237</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>239</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.013086</td>
      <td>0.385580</td>
      <td>0.013086</td>
      <td>0.997162</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1504</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,250.0,32,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.030303</td>
      <td>0.294131</td>
      <td>0.030303</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1505</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,250.0,32,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.028268</td>
      <td>0.999341</td>
      <td>-0.028268</td>
      <td>0.345334</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1506</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,250.0,32,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>79.0 (73.9 to 83.2)</td>
      <td>Non-Inferiority</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>229</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>234</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.046059</td>
      <td>1.000000</td>
      <td>-0.046059</td>
      <td>0.101123</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1507</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,250.0,32,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.4 (78.7 to 87.2)</td>
      <td>Non-Inferiority</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>237</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>239</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.013086</td>
      <td>0.385580</td>
      <td>0.013086</td>
      <td>0.997162</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1508</th>
      <td>acute</td>
      <td>16</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.030303</td>
      <td>0.294131</td>
      <td>0.030303</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1509</th>
      <td>acute</td>
      <td>16</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.028268</td>
      <td>0.999341</td>
      <td>-0.028268</td>
      <td>0.345334</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1510</th>
      <td>acute</td>
      <td>16</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>79.0 (73.9 to 83.2)</td>
      <td>Non-Inferiority</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>229</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>234</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.046059</td>
      <td>1.000000</td>
      <td>-0.046059</td>
      <td>0.101123</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1511</th>
      <td>acute</td>
      <td>16</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.4 (78.7 to 87.2)</td>
      <td>Non-Inferiority</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>237</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>239</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.013086</td>
      <td>0.385580</td>
      <td>0.013086</td>
      <td>0.997162</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1512</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>32</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,32,32,32,33,4.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>2.699885e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>67</td>
      <td>58</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.058571</td>
      <td>0.149872</td>
      <td>0.058571</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1513</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>32</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,32,32,32,33,4.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>2.699885e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>61</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.058571</td>
      <td>1.000000</td>
      <td>-0.058571</td>
      <td>0.149872</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1514</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,33,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.929379e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>67</td>
      <td>58</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.058571</td>
      <td>0.149872</td>
      <td>0.058571</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1515</th>
      <td>acute</td>
      <td>33</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,33,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>-0.030303</td>
      <td>9.999999e-01</td>
      <td>-0.030303</td>
      <td>3.929379e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>61</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.058571</td>
      <td>1.000000</td>
      <td>-0.058571</td>
      <td>0.149872</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1516</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,250.0,32,32,4.0,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>67</td>
      <td>58</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.058571</td>
      <td>0.149872</td>
      <td>0.058571</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1517</th>
      <td>acute</td>
      <td>32</td>
      <td>32</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,250.0,32,32,4.0,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>61</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.058571</td>
      <td>1.000000</td>
      <td>-0.058571</td>
      <td>0.149872</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1518</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>32</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>59</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>59</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>61</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.030303</td>
      <td>0.999341</td>
      <td>-0.030303</td>
      <td>0.294131</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1519</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>32</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>59</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>59</td>
      <td>antibiotic</td>
      <td>67</td>
      <td>58</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.028268</td>
      <td>0.345334</td>
      <td>0.028268</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1520</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>32</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>280</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.6 (78.8 to 87.4)</td>
      <td>NaN</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>234</td>
      <td>antibiotic</td>
      <td>290</td>
      <td>229</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.046059</td>
      <td>0.101123</td>
      <td>0.046059</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1521</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>32</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,20.0,20.0,20.0,2012,22802252,24,24,32,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>0.000000</td>
      <td>9.997600e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>292</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>82.1 (77.2 to 85.9)</td>
      <td>NaN</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>239</td>
      <td>antibiotic</td>
      <td>285</td>
      <td>237</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.013086</td>
      <td>0.997162</td>
      <td>-0.013086</td>
      <td>0.385580</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1522</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>59</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>59</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>61</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.030303</td>
      <td>0.999341</td>
      <td>-0.030303</td>
      <td>0.294131</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1523</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>59</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>59</td>
      <td>antibiotic</td>
      <td>67</td>
      <td>58</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.028268</td>
      <td>0.345334</td>
      <td>0.028268</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1524</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>280</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.6 (78.8 to 87.4)</td>
      <td>NaN</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>234</td>
      <td>antibiotic</td>
      <td>290</td>
      <td>229</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.046059</td>
      <td>0.101123</td>
      <td>0.046059</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1525</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>292</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>82.1 (77.2 to 85.9)</td>
      <td>NaN</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>239</td>
      <td>antibiotic</td>
      <td>285</td>
      <td>237</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.013086</td>
      <td>0.997162</td>
      <td>-0.013086</td>
      <td>0.385580</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1526</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>59</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>59</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>61</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.030303</td>
      <td>0.999341</td>
      <td>-0.030303</td>
      <td>0.294131</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1527</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>59</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>59</td>
      <td>antibiotic</td>
      <td>67</td>
      <td>58</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.028268</td>
      <td>0.345334</td>
      <td>0.028268</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1528</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>280</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.6 (78.8 to 87.4)</td>
      <td>NaN</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>234</td>
      <td>antibiotic</td>
      <td>290</td>
      <td>229</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.046059</td>
      <td>0.101123</td>
      <td>0.046059</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1529</th>
      <td>acute</td>
      <td>24</td>
      <td>24</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>16</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,16,16,20.0,20.0,2012,22802252,24,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>0.000000</td>
      <td>9.998400e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>292</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>82.1 (77.2 to 85.9)</td>
      <td>NaN</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>239</td>
      <td>antibiotic</td>
      <td>285</td>
      <td>237</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.013086</td>
      <td>0.997162</td>
      <td>-0.013086</td>
      <td>0.385580</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1530</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>21</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,21,22802252,24,25,33,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.117424</td>
      <td>9.999999e-01</td>
      <td>-0.117424</td>
      <td>2.057571e-01</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077244</td>
      <td>0.271120</td>
      <td>-0.077244</td>
      <td>0.999411</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1531</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>21</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,21,22802252,24,25,33,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.117424</td>
      <td>9.999999e-01</td>
      <td>-0.117424</td>
      <td>2.057571e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.183518</td>
      <td>0.013105</td>
      <td>-0.183518</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1532</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>21</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,21,22802252,24,25,33,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.117424</td>
      <td>9.999999e-01</td>
      <td>-0.117424</td>
      <td>2.057571e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>60.6 (55.0 to 66.0)</td>
      <td>not superior</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>175</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>171</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.007266</td>
      <td>0.997212</td>
      <td>-0.007266</td>
      <td>0.455437</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1533</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>21</td>
      <td>20.00</td>
      <td>100.0</td>
      <td>100.0,100.0,12.0,20.0,20.0,20.0,2012,21,22802252,24,25,33,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.117424</td>
      <td>9.999999e-01</td>
      <td>-0.117424</td>
      <td>2.057571e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>63.3 (57.7 to 68.7)</td>
      <td>not superior</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>180</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>172</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.042538</td>
      <td>0.152620</td>
      <td>0.042538</td>
      <td>0.999996</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1534</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,13,20.0,20.0,20.0,2012,22802252,24,25,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215909</td>
      <td>4.913946e-02</td>
      <td>0.215909</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077244</td>
      <td>0.271120</td>
      <td>-0.077244</td>
      <td>0.999411</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1535</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,13,20.0,20.0,20.0,2012,22802252,24,25,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215909</td>
      <td>4.913946e-02</td>
      <td>0.215909</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.183518</td>
      <td>0.013105</td>
      <td>-0.183518</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1536</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,13,20.0,20.0,20.0,2012,22802252,24,25,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215909</td>
      <td>4.913946e-02</td>
      <td>0.215909</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>60.6 (55.0 to 66.0)</td>
      <td>not superior</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>175</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>171</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.007266</td>
      <td>0.997212</td>
      <td>-0.007266</td>
      <td>0.455437</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1537</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,13,20.0,20.0,20.0,2012,22802252,24,25,33,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.215909</td>
      <td>4.913946e-02</td>
      <td>0.215909</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>63.3 (57.7 to 68.7)</td>
      <td>not superior</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>180</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>172</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.042538</td>
      <td>0.152620</td>
      <td>0.042538</td>
      <td>0.999996</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1538</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,11,12.0,16,20.0,20.0,2012,22802252,25,250.0,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.070076</td>
      <td>4.003825e-01</td>
      <td>0.070076</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077244</td>
      <td>0.271120</td>
      <td>-0.077244</td>
      <td>0.999411</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1539</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,11,12.0,16,20.0,20.0,2012,22802252,25,250.0,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.070076</td>
      <td>4.003825e-01</td>
      <td>0.070076</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.183518</td>
      <td>0.013105</td>
      <td>-0.183518</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1540</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,11,12.0,16,20.0,20.0,2012,22802252,25,250.0,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.070076</td>
      <td>4.003825e-01</td>
      <td>0.070076</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>60.6 (55.0 to 66.0)</td>
      <td>not superior</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>175</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>171</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.007266</td>
      <td>0.997212</td>
      <td>-0.007266</td>
      <td>0.455437</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1541</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,11,12.0,16,20.0,20.0,2012,22802252,25,250.0,33,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.070076</td>
      <td>4.003825e-01</td>
      <td>0.070076</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>63.3 (57.7 to 68.7)</td>
      <td>not superior</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>180</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>172</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.042538</td>
      <td>0.152620</td>
      <td>0.042538</td>
      <td>0.999996</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1542</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,13,16,20.0,20.0,20.0,2012,22802252,24,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.041667</td>
      <td>9.997601e-01</td>
      <td>-0.041667</td>
      <td>4.327797e-01</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077244</td>
      <td>0.271120</td>
      <td>-0.077244</td>
      <td>0.999411</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1543</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,13,16,20.0,20.0,20.0,2012,22802252,24,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.041667</td>
      <td>9.997601e-01</td>
      <td>-0.041667</td>
      <td>4.327797e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.183518</td>
      <td>0.013105</td>
      <td>-0.183518</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1544</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,13,16,20.0,20.0,20.0,2012,22802252,24,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.041667</td>
      <td>9.997601e-01</td>
      <td>-0.041667</td>
      <td>4.327797e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>60.6 (55.0 to 66.0)</td>
      <td>not superior</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>175</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>171</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.007266</td>
      <td>0.997212</td>
      <td>-0.007266</td>
      <td>0.455437</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1545</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>24</td>
      <td>13</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>12.0,13,16,20.0,20.0,20.0,2012,22802252,24,32,4.0,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.041667</td>
      <td>9.997601e-01</td>
      <td>-0.041667</td>
      <td>4.327797e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>63.3 (57.7 to 68.7)</td>
      <td>not superior</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>180</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>172</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.042538</td>
      <td>0.152620</td>
      <td>0.042538</td>
      <td>0.999996</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1546</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.187500</td>
      <td>1.000000e+00</td>
      <td>-0.187500</td>
      <td>1.839360e-01</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077244</td>
      <td>0.271120</td>
      <td>-0.077244</td>
      <td>0.999411</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1547</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.187500</td>
      <td>1.000000e+00</td>
      <td>-0.187500</td>
      <td>1.839360e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.183518</td>
      <td>0.013105</td>
      <td>-0.183518</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1548</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.187500</td>
      <td>1.000000e+00</td>
      <td>-0.187500</td>
      <td>1.839360e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>60.6 (55.0 to 66.0)</td>
      <td>not superior</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>175</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>171</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.007266</td>
      <td>0.997212</td>
      <td>-0.007266</td>
      <td>0.455437</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1549</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,16,16,20.0,20.0,2012,22802252,250.0,32,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.187500</td>
      <td>1.000000e+00</td>
      <td>-0.187500</td>
      <td>1.839360e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>63.3 (57.7 to 68.7)</td>
      <td>not superior</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>180</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>172</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.042538</td>
      <td>0.152620</td>
      <td>0.042538</td>
      <td>0.999996</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1550</th>
      <td>sustained</td>
      <td>16</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,13,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.125000</td>
      <td>2.634346e-01</td>
      <td>0.125000</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077244</td>
      <td>0.271120</td>
      <td>-0.077244</td>
      <td>0.999411</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1551</th>
      <td>sustained</td>
      <td>16</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,13,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.125000</td>
      <td>2.634346e-01</td>
      <td>0.125000</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.183518</td>
      <td>0.013105</td>
      <td>-0.183518</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1552</th>
      <td>sustained</td>
      <td>16</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,13,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.125000</td>
      <td>2.634346e-01</td>
      <td>0.125000</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>60.6 (55.0 to 66.0)</td>
      <td>not superior</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>175</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>171</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.007266</td>
      <td>0.997212</td>
      <td>-0.007266</td>
      <td>0.455437</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1553</th>
      <td>sustained</td>
      <td>16</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>11</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>11,12.0,13,16,16,20.0,2012,22802252,250.0,250.0,50.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.125000</td>
      <td>2.634346e-01</td>
      <td>0.125000</td>
      <td>9.998400e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>63.3 (57.7 to 68.7)</td>
      <td>not superior</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>180</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>172</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.042538</td>
      <td>0.152620</td>
      <td>0.042538</td>
      <td>0.999996</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1554</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>16</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,16,20.0,20.0,20.0,2012,22802252,25,32,33,4.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.257576</td>
      <td>1.733822e-02</td>
      <td>0.257576</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>58</td>
      <td>10</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.106275</td>
      <td>1.000000</td>
      <td>0.106275</td>
      <td>0.112307</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1555</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>16</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,16,20.0,20.0,20.0,2012,22802252,25,32,33,4.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.257576</td>
      <td>1.733822e-02</td>
      <td>0.257576</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>61</td>
      <td>17</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.106275</td>
      <td>0.112307</td>
      <td>-0.106275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1556</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,13,16,20.0,20.0,2012,22802252,25,250.0,33,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.054924</td>
      <td>9.998400e-01</td>
      <td>-0.054924</td>
      <td>4.004828e-01</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>58</td>
      <td>10</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.106275</td>
      <td>1.000000</td>
      <td>0.106275</td>
      <td>0.112307</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1557</th>
      <td>sustained</td>
      <td>33</td>
      <td>25</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,13,16,20.0,20.0,2012,22802252,25,250.0,33,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.054924</td>
      <td>9.998400e-01</td>
      <td>-0.054924</td>
      <td>4.004828e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>61</td>
      <td>17</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.106275</td>
      <td>0.112307</td>
      <td>-0.106275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1558</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,13,16,16,20.0,20.0,2012,22802252,250.0,32,4.0,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.312500</td>
      <td>1.000000e+00</td>
      <td>-0.312500</td>
      <td>2.252705e-02</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>58</td>
      <td>10</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.106275</td>
      <td>1.000000</td>
      <td>0.106275</td>
      <td>0.112307</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1559</th>
      <td>sustained</td>
      <td>32</td>
      <td>16</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,13,16,16,20.0,20.0,2012,22802252,250.0,32,4.0,50.0,ATCC 43596,CB-183,315,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.312500</td>
      <td>1.000000e+00</td>
      <td>-0.312500</td>
      <td>2.252705e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>CB-183,315</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>61</td>
      <td>17</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>-0.106275</td>
      <td>0.112307</td>
      <td>-0.106275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1560</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>16</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,16,20.0,20.0,20.0,2012,21,22802252,24,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.375000</td>
      <td>1.787418e-03</td>
      <td>0.375000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>59</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>21</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>21</td>
      <td>antibiotic</td>
      <td>61</td>
      <td>17</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>0.077244</td>
      <td>0.999411</td>
      <td>0.077244</td>
      <td>0.271120</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1561</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>16</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,16,20.0,20.0,20.0,2012,21,22802252,24,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.375000</td>
      <td>1.787418e-03</td>
      <td>0.375000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>59</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>21</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>21</td>
      <td>antibiotic</td>
      <td>58</td>
      <td>10</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.183518</td>
      <td>1.000000</td>
      <td>0.183518</td>
      <td>0.013105</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1562</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>16</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,16,20.0,20.0,20.0,2012,21,22802252,24,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.375000</td>
      <td>1.787418e-03</td>
      <td>0.375000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>280</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>61.4 (55.9 to 66.8)</td>
      <td>NaN</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>171</td>
      <td>antibiotic</td>
      <td>290</td>
      <td>175</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.007266</td>
      <td>0.455437</td>
      <td>0.007266</td>
      <td>0.997212</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1563</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>32</td>
      <td>16</td>
      <td>4.00</td>
      <td>20.0</td>
      <td>100.0,12.0,16,20.0,20.0,20.0,2012,21,22802252,24,32,4.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.375000</td>
      <td>1.787418e-03</td>
      <td>0.375000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>292</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>59.0 (53.4 to 64.5)</td>
      <td>NaN</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>172</td>
      <td>antibiotic</td>
      <td>285</td>
      <td>180</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.042538</td>
      <td>0.999996</td>
      <td>-0.042538</td>
      <td>0.152620</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1564</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,13,16,20.0,20.0,2012,21,22802252,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.062500</td>
      <td>3.557817e-01</td>
      <td>0.062500</td>
      <td>9.998401e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>59</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>21</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>21</td>
      <td>antibiotic</td>
      <td>61</td>
      <td>17</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>0.077244</td>
      <td>0.999411</td>
      <td>0.077244</td>
      <td>0.271120</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1565</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,13,16,20.0,20.0,2012,21,22802252,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.062500</td>
      <td>3.557817e-01</td>
      <td>0.062500</td>
      <td>9.998401e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>59</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>21</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>21</td>
      <td>antibiotic</td>
      <td>58</td>
      <td>10</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.183518</td>
      <td>1.000000</td>
      <td>0.183518</td>
      <td>0.013105</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1566</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,13,16,20.0,20.0,2012,21,22802252,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.062500</td>
      <td>3.557817e-01</td>
      <td>0.062500</td>
      <td>9.998401e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>280</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>61.4 (55.9 to 66.8)</td>
      <td>NaN</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>171</td>
      <td>antibiotic</td>
      <td>290</td>
      <td>175</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.007266</td>
      <td>0.455437</td>
      <td>0.007266</td>
      <td>0.997212</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1567</th>
      <td>sustained</td>
      <td>24</td>
      <td>21</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>100.0,12.0,13,16,20.0,20.0,2012,21,22802252,24,250.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>0.062500</td>
      <td>3.557817e-01</td>
      <td>0.062500</td>
      <td>9.998401e-01</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>292</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>59.0 (53.4 to 64.5)</td>
      <td>NaN</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>172</td>
      <td>antibiotic</td>
      <td>285</td>
      <td>180</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.042538</td>
      <td>0.999996</td>
      <td>-0.042538</td>
      <td>0.152620</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1568</th>
      <td>sustained</td>
      <td>24</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,13,13,16,20.0,20.0,2012,22802252,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.270833</td>
      <td>1.000000e+00</td>
      <td>-0.270833</td>
      <td>6.240001e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>59</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>21</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>21</td>
      <td>antibiotic</td>
      <td>61</td>
      <td>17</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>0.077244</td>
      <td>0.999411</td>
      <td>0.077244</td>
      <td>0.271120</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1569</th>
      <td>sustained</td>
      <td>24</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,13,13,16,20.0,20.0,2012,22802252,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.270833</td>
      <td>1.000000e+00</td>
      <td>-0.270833</td>
      <td>6.240001e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>yes</td>
      <td>59</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>21</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>21</td>
      <td>antibiotic</td>
      <td>58</td>
      <td>10</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.183518</td>
      <td>1.000000</td>
      <td>0.183518</td>
      <td>0.013105</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1570</th>
      <td>sustained</td>
      <td>24</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,13,13,16,20.0,20.0,2012,22802252,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.270833</td>
      <td>1.000000e+00</td>
      <td>-0.270833</td>
      <td>6.240001e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>280</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>61.4 (55.9 to 66.8)</td>
      <td>NaN</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>171</td>
      <td>antibiotic</td>
      <td>290</td>
      <td>175</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.007266</td>
      <td>0.455437</td>
      <td>0.007266</td>
      <td>0.997212</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1571</th>
      <td>sustained</td>
      <td>24</td>
      <td>13</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>4.00</td>
      <td>20.00</td>
      <td>CB-183,315</td>
      <td>therapeutic</td>
      <td>16</td>
      <td>13</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>12.0,13,13,16,20.0,20.0,2012,22802252,24,250.0,4.0,50.0,ATCC 43596,CB-183,315,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.270833</td>
      <td>1.000000e+00</td>
      <td>-0.270833</td>
      <td>6.240001e-02</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>292</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>59.0 (53.4 to 64.5)</td>
      <td>NaN</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>172</td>
      <td>antibiotic</td>
      <td>285</td>
      <td>180</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.042538</td>
      <td>0.999996</td>
      <td>-0.042538</td>
      <td>0.152620</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1572</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2.5,2.5,20.0,2015,25993059,8,8,8,8,ATCC 43596,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>yes</td>
      <td>66</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>61</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>61</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.030303</td>
      <td>0.294131</td>
      <td>0.030303</td>
      <td>0.999341</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1573</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2.5,2.5,20.0,2015,25993059,8,8,8,8,ATCC 43596,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>yes</td>
      <td>67</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>58</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>58</td>
      <td>antibiotic</td>
      <td>66</td>
      <td>59</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.028268</td>
      <td>0.999341</td>
      <td>-0.028268</td>
      <td>0.345334</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1574</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2.5,2.5,20.0,2015,25993059,8,8,8,8,ATCC 43596,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>79.0 (73.9 to 83.2)</td>
      <td>Non-Inferiority</td>
      <td>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>229</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>234</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.046059</td>
      <td>1.000000</td>
      <td>-0.046059</td>
      <td>0.101123</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1575</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2.5,2.5,20.0,2015,25993059,8,8,8,8,ATCC 43596,Golden Syrian,M,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>83.4 (78.7 to 87.2)</td>
      <td>Non-Inferiority</td>
      <td>Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was &gt; -10%.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>237</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>239</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.013086</td>
      <td>0.385580</td>
      <td>0.013086</td>
      <td>0.997162</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1576</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>2</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2,2.5,2.5,20.0,2015,25993059,8,8,8,ATCC 43596,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,sustained,t,t,vancomycin</td>
      <td>0.750000</td>
      <td>1.113892e-03</td>
      <td>0.750000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>250.0</td>
      <td>2500.0</td>
      <td>125</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>yes</td>
      <td>61</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>17</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>17</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.077244</td>
      <td>0.271120</td>
      <td>-0.077244</td>
      <td>0.999411</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1577</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>2</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2,2.5,2.5,20.0,2015,25993059,8,8,8,ATCC 43596,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,sustained,t,t,vancomycin</td>
      <td>0.750000</td>
      <td>1.113892e-03</td>
      <td>0.750000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>yes</td>
      <td>58</td>
      <td>therapeutic</td>
      <td>Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period</td>
      <td>negative</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>1</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>59</td>
      <td>21</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.183518</td>
      <td>0.013105</td>
      <td>-0.183518</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1578</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>2</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2,2.5,2.5,20.0,2015,25993059,8,8,8,ATCC 43596,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,sustained,t,t,vancomycin</td>
      <td>0.750000</td>
      <td>1.113892e-03</td>
      <td>0.750000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>no</td>
      <td>290</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>60.6 (55.0 to 66.0)</td>
      <td>not superior</td>
      <td>The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>175</td>
      <td>antibiotic</td>
      <td>280</td>
      <td>171</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.007266</td>
      <td>0.997212</td>
      <td>-0.007266</td>
      <td>0.455437</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1579</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>ATCC 43596</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>20.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>0.50</td>
      <td>2.50</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>2</td>
      <td>0.50</td>
      <td>2.5</td>
      <td>0.5,0.5,12.0,2,2.5,2.5,20.0,2015,25993059,8,8,8,ATCC 43596,Golden Syrian,M,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,surotomycin,sustained,t,t,vancomycin</td>
      <td>0.750000</td>
      <td>1.113892e-03</td>
      <td>0.750000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>250</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>surotomycin</td>
      <td>no</td>
      <td>285</td>
      <td>therapeutic</td>
      <td>Adjusted Percentage of Participants With Sustained Clinical Response at End of Study</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>63.3 (57.7 to 68.7)</td>
      <td>not superior</td>
      <td>Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was &gt; 0.</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 89 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>180</td>
      <td>antibiotic</td>
      <td>292</td>
      <td>172</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.042538</td>
      <td>0.152620</td>
      <td>0.042538</td>
      <td>0.999996</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1580</th>
      <td>sustained</td>
      <td>15</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>80.00</td>
      <td>CDA1 + MDX1388</td>
      <td>therapeutic</td>
      <td>22</td>
      <td>15</td>
      <td>80.00</td>
      <td>320.0</td>
      <td>140000.0,15,15,16966409,20.0,2006,22,320.0,4,75.0,80.0,80.0,87.0,CDA1 + MDX1388,CFU,Golden Syrian,MDX1388,VPI 10463,clindamycin+challenge+vancomycin,cumulative mortality,hamster,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.415152</td>
      <td>1.000000e+00</td>
      <td>-0.415152</td>
      <td>8.153987e-03</td>
      <td>sustained</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>MDX1388</td>
      <td>no</td>
      <td>390</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>14.9</td>
      <td>Superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>58</td>
      <td>antibody</td>
      <td>395</td>
      <td>62</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>-0.008244</td>
      <td>0.412988</td>
      <td>-0.008244</td>
      <td>0.996123</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1581</th>
      <td>sustained</td>
      <td>15</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>80.00</td>
      <td>CDA1 + MDX1388</td>
      <td>therapeutic</td>
      <td>22</td>
      <td>15</td>
      <td>80.00</td>
      <td>320.0</td>
      <td>140000.0,15,15,16966409,20.0,2006,22,320.0,4,75.0,80.0,80.0,87.0,CDA1 + MDX1388,CFU,Golden Syrian,MDX1388,VPI 10463,clindamycin+challenge+vancomycin,cumulative mortality,hamster,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.415152</td>
      <td>1.000000e+00</td>
      <td>-0.415152</td>
      <td>8.153987e-03</td>
      <td>sustained</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>MDX1388</td>
      <td>no</td>
      <td>386</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>17.4</td>
      <td>superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>67</td>
      <td>antibody</td>
      <td>383</td>
      <td>60</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>0.016917</td>
      <td>0.996192</td>
      <td>0.016917</td>
      <td>0.278497</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1582</th>
      <td>sustained</td>
      <td>15</td>
      <td>4</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>20.00</td>
      <td>80.00</td>
      <td>CDA1</td>
      <td>therapeutic</td>
      <td>86</td>
      <td>28</td>
      <td>60.00</td>
      <td>240.0</td>
      <td>140000.0,15,16966409,20.0,2006,240.0,28,4,60.0,75.0,80.0,86,87.0,CDA1,CFU,Golden Syrian,MDX1388,VPI 10463,clindamycin+challenge+vancomycin,cumulative mortality,hamster,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.058915</td>
      <td>9.999996e-01</td>
      <td>-0.058915</td>
      <td>4.744268e-01</td>
      <td>sustained</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>MDX1388</td>
      <td>no</td>
      <td>386</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>17.4</td>
      <td>superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>67</td>
      <td>antibody</td>
      <td>232</td>
      <td>60</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>-0.085046</td>
      <td>0.007786</td>
      <td>-0.085046</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1583</th>
      <td>sustained</td>
      <td>22</td>
      <td>15</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>87.0</td>
      <td>VPI 10463</td>
      <td>NaN</td>
      <td>75.0</td>
      <td>140000.0</td>
      <td>CFU</td>
      <td>spores</td>
      <td>80.00</td>
      <td>320.00</td>
      <td>CDA1</td>
      <td>therapeutic</td>
      <td>86</td>
      <td>28</td>
      <td>60.00</td>
      <td>240.0</td>
      <td>140000.0,15,16966409,2006,22,240.0,28,320.0,60.0,75.0,80.0,86,87.0,CDA1,CDA1 + MDX1388,CFU,Golden Syrian,VPI 10463,clindamycin+challenge+vancomycin,cumulative mortality,hamster,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.356237</td>
      <td>3.871023e-03</td>
      <td>0.356237</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>20.0</td>
      <td>20.0</td>
      <td>10 and 10</td>
      <td>mg/kg</td>
      <td>QD</td>
      <td>1.0</td>
      <td>NaN</td>
      <td>antibody</td>
      <td>CDA1 + MDX1388</td>
      <td>no</td>
      <td>383</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With CDI Recurrence</td>
      <td>negative</td>
      <td>Percentage of participants</td>
      <td>15.9</td>
      <td>not superior</td>
      <td>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>60</td>
      <td>antibody</td>
      <td>232</td>
      <td>60</td>
      <td>10.0</td>
      <td>10.0</td>
      <td>-0.101963</td>
      <td>0.001306</td>
      <td>-0.101963</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1584</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10.0,12.0,125.0,2.0,2015,225.0,25.0,25652749,3,630,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.700000</td>
      <td>1.000000e+00</td>
      <td>-0.700000</td>
      <td>4.364049e-04</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1585</th>
      <td>sustained</td>
      <td>10</td>
      <td>3</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10.0,12.0,2.0,2015,225.0,250.0,25652749,3,50.0,630,8,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.500000</td>
      <td>1.000000e+00</td>
      <td>-0.500000</td>
      <td>2.069473e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1586</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0,10,10,10,100.0,12.0,125.0,20.0,2015,225.0,25.0,25652749,630,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1587</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,8,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.058578e-04</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1588</th>
      <td>sustained</td>
      <td>10</td>
      <td>4</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,12.0,2015,225.0,25.0,250.0,25652749,4,5.0,50.0,630,8,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>4.743900e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1589</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>50.00</td>
      <td>250.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,12.0,2015,225.0,250.0,250.0,25652749,50.0,50.0,630,8,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.058578e-04</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1590</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10.0,125.0,2.0,2015,225.0,25.0,25652749,27.0,9,9,BI1,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1591</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>2.00</td>
      <td>10.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10.0,2.0,2015,225.0,250.0,25652749,27.0,50.0,9,BI1,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>1.000000e+00</td>
      <td>-0.100000</td>
      <td>2.610429e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1592</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,2015,225.0,25.0,250.0,25652749,27.0,5.0,50.0,9,BI1,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>-0.100000</td>
      <td>1.000000e+00</td>
      <td>-0.100000</td>
      <td>2.610429e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>fidaxomicin</td>
      <td>no</td>
      <td>13</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>6</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>6</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>7</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.038462</td>
      <td>0.999870</td>
      <td>-0.038462</td>
      <td>0.471129</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1593</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,12.0,125.0,20.0,2015,225.0,25.0,25652749,630,Golden Syrian,SMT19969,SPF,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>33</td>
      <td>therapeutic</td>
      <td>Clinical response at test of cure</td>
      <td>positive</td>
      <td>participants</td>
      <td>23</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>36</td>
      <td>28</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.080808</td>
      <td>0.999670</td>
      <td>-0.080808</td>
      <td>0.281872</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1594</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,Golden Syrian,SMT19969,SPF,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>33</td>
      <td>therapeutic</td>
      <td>Clinical response at test of cure</td>
      <td>positive</td>
      <td>participants</td>
      <td>23</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>36</td>
      <td>28</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.080808</td>
      <td>0.999670</td>
      <td>-0.080808</td>
      <td>0.281872</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1595</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>10,10,10,10,100.0,125.0,20.0,2015,225.0,25.0,25652749,27.0,BI1,Golden Syrian,SMT19969,SPF,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>33</td>
      <td>therapeutic</td>
      <td>Clinical response at test of cure</td>
      <td>positive</td>
      <td>participants</td>
      <td>23</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>36</td>
      <td>28</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.080808</td>
      <td>0.999670</td>
      <td>-0.080808</td>
      <td>0.281872</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1596</th>
      <td>acute</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>10,10,10,10,100.0,20.0,2015,225.0,250.0,25652749,27.0,50.0,BI1,Golden Syrian,SMT19969,SPF,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>acute</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>33</td>
      <td>therapeutic</td>
      <td>Clinical response at test of cure</td>
      <td>positive</td>
      <td>participants</td>
      <td>23</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>36</td>
      <td>28</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.080808</td>
      <td>0.999670</td>
      <td>-0.080808</td>
      <td>0.281872</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1597</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>0,10,10,10,100.0,12.0,125.0,20.0,2015,225.0,25.0,25652749,630,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.536743e-07</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>23</td>
      <td>therapeutic</td>
      <td>Sustained clinical response</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>inferior</td>
      <td>wald</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>28</td>
      <td>24</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.248447</td>
      <td>1.000000</td>
      <td>-0.248447</td>
      <td>0.025288</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1598</th>
      <td>sustained</td>
      <td>10</td>
      <td>0</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>8</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,100.0,12.0,20.0,2015,225.0,250.0,25652749,50.0,630,8,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>1.058578e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>23</td>
      <td>therapeutic</td>
      <td>Sustained clinical response</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>inferior</td>
      <td>wald</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>28</td>
      <td>24</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.248447</td>
      <td>1.000000</td>
      <td>-0.248447</td>
      <td>0.025288</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1599</th>
      <td>sustained</td>
      <td>10</td>
      <td>1</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>25.00</td>
      <td>125.0</td>
      <td>1,10,10,100.0,125.0,20.0,2015,225.0,25.0,25652749,27.0,9,BI1,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.800000</td>
      <td>1.000000e+00</td>
      <td>-0.800000</td>
      <td>2.012253e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>23</td>
      <td>therapeutic</td>
      <td>Sustained clinical response</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>inferior</td>
      <td>wald</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>28</td>
      <td>24</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.248447</td>
      <td>1.000000</td>
      <td>-0.248447</td>
      <td>0.025288</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1600</th>
      <td>sustained</td>
      <td>10</td>
      <td>1</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>20.00</td>
      <td>100.00</td>
      <td>SMT19969</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>10</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>1,10,10,10,100.0,20.0,2015,225.0,250.0,25652749,27.0,50.0,BI1,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t,vancomycin</td>
      <td>-0.900000</td>
      <td>1.000000e+00</td>
      <td>-0.900000</td>
      <td>2.002716e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>23</td>
      <td>therapeutic</td>
      <td>Sustained clinical response</td>
      <td>positive</td>
      <td>participants</td>
      <td>14</td>
      <td>inferior</td>
      <td>wald</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 90 Years Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>14</td>
      <td>antibiotic</td>
      <td>28</td>
      <td>24</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.248447</td>
      <td>1.000000</td>
      <td>-0.248447</td>
      <td>0.025288</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1601</th>
      <td>sustained</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>4</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,10,12.0,125.0,2015,225.0,25.0,25.0,25652749,4,5.0,630,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.600000</td>
      <td>1.758278e-03</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>SMT19969</td>
      <td>no</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>antibiotic</td>
      <td>13</td>
      <td>6</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.038462</td>
      <td>0.471129</td>
      <td>0.038462</td>
      <td>0.999870</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1602</th>
      <td>sustained</td>
      <td>10</td>
      <td>10</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>12.0</td>
      <td>630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>0</td>
      <td>50.00</td>
      <td>250.0</td>
      <td>0,10,10,10,12.0,125.0,2015,225.0,25.0,250.0,25652749,50.0,630,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>1.000000</td>
      <td>9.536743e-07</td>
      <td>1.000000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>SMT19969</td>
      <td>no</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>antibiotic</td>
      <td>13</td>
      <td>6</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.038462</td>
      <td>0.471129</td>
      <td>0.038462</td>
      <td>0.999870</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1603</th>
      <td>sustained</td>
      <td>10</td>
      <td>9</td>
      <td>positive</td>
      <td>SPF</td>
      <td>Golden Syrian</td>
      <td>NaN</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>27.0</td>
      <td>BI1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>225.0</td>
      <td>NaN</td>
      <td>spores</td>
      <td>25.00</td>
      <td>125.00</td>
      <td>fidaxomicin</td>
      <td>therapeutic</td>
      <td>10</td>
      <td>9</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>10,10,125.0,2015,225.0,25.0,25.0,25652749,27.0,5.0,9,9,BI1,Golden Syrian,SMT19969,SPF,clindamycin+challenge,cumulative mortality,fidaxomicin,hamster,nan,nan,nan,nan,positive,spores,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>0.000000</td>
      <td>9.999000e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>SMT19969</td>
      <td>no</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>7</td>
      <td>equivalence</td>
      <td>estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>7</td>
      <td>antibiotic</td>
      <td>13</td>
      <td>6</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.038462</td>
      <td>0.471129</td>
      <td>0.038462</td>
      <td>0.999870</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1604</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1605</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1606</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1607</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1608</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1609</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1610</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1611</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1612</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1613</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1614</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1615</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1616</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1617</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1618</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1619</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1620</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1621</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1622</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,2926,3,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1623</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,2926,3,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1624</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,2926,3,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1625</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,2926,3,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1626</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,2926,3,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1627</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>3</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,2926,3,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1628</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1629</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1630</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1631</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1632</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1633</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1634</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1635</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1636</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1637</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1638</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1639</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1640</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1641</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1642</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1643</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1644</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1645</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1646</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1647</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1648</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1649</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1650</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1651</th>
      <td>acute</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1652</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Clinical cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>87</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>87</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>95</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.043091</td>
      <td>0.998962</td>
      <td>-0.043091</td>
      <td>0.272350</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1653</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]</td>
      <td>positive</td>
      <td>participants</td>
      <td>8</td>
      <td>NaN</td>
      <td>chi^2 and Kruskal-Wallis anova</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>8</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>3</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.145833</td>
      <td>0.191477</td>
      <td>0.145833</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1654</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>98</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.6 (68.0 to 85.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>76</td>
      <td>antibiotic</td>
      <td>44</td>
      <td>31</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.070965</td>
      <td>0.247704</td>
      <td>0.070965</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1655</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>9</td>
      <td>6</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.250000</td>
      <td>0.102258</td>
      <td>0.250000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1656</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200mg BID for 10 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>7</td>
      <td>therapeutic</td>
      <td>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</td>
      <td>positive</td>
      <td>participants</td>
      <td>4</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>4</td>
      <td>antibiotic</td>
      <td>5</td>
      <td>5</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.428571</td>
      <td>1.000000</td>
      <td>-0.428571</td>
      <td>0.071994</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1657</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>clinical reponse 2 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>138</td>
      <td>NaN</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>138</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>147</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.041568</td>
      <td>0.998235</td>
      <td>-0.041568</td>
      <td>0.267029</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1658</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1659</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1660</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1661</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1662</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1663</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1664</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1665</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1666</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1667</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1668</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1669</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1670</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1671</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1672</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1673</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1674</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1675</th>
      <td>acute</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1676</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>-0.085714</td>
      <td>0.999860</td>
      <td>-0.085714</td>
      <td>0.361195</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1677</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>14</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>10</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>10</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.223214</td>
      <td>1.000000</td>
      <td>-0.223214</td>
      <td>0.067690</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1678</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.085714</td>
      <td>0.361195</td>
      <td>0.085714</td>
      <td>0.999860</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1679</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>12</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>12</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>15</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.137500</td>
      <td>1.000000</td>
      <td>-0.137500</td>
      <td>0.156275</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1680</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>14</td>
      <td>10</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>0.223214</td>
      <td>0.067690</td>
      <td>0.223214</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1681</th>
      <td>acute</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,acute,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>acute</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>Relief of symptoms of CDAD</td>
      <td>positive</td>
      <td>participants</td>
      <td>15</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>15</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>12</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.137500</td>
      <td>0.156275</td>
      <td>0.137500</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1682</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>1.000000</td>
      <td>1.525879e-05</td>
      <td>1.000000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1683</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>1.000000</td>
      <td>1.525879e-05</td>
      <td>1.000000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1684</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>1.000000</td>
      <td>1.525879e-05</td>
      <td>1.000000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1685</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>0</td>
      <td>0.20</td>
      <td>1.0</td>
      <td>0,0.2,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>1.000000</td>
      <td>1.525879e-05</td>
      <td>1.000000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1686</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1687</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1688</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1689</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1690</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1691</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1692</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1693</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1694</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,1.0,1.0,1000000.0,1929250,1991,2926,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.600000</td>
      <td>3.092405e-02</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1695</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,1.0,1.0,1000000.0,1929250,1991,2926,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.600000</td>
      <td>3.092405e-02</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1696</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,1.0,1.0,1000000.0,1929250,1991,2926,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.600000</td>
      <td>3.092405e-02</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1697</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>0</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,1.0,1.0,1000000.0,1929250,1991,2926,3,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.600000</td>
      <td>3.092405e-02</td>
      <td>0.600000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1698</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1699</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1700</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1701</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1702</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1703</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1704</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1705</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>1</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>1,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.875000</td>
      <td>2.593994e-04</td>
      <td>0.875000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1706</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1707</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1708</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1709</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1710</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1711</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1712</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1713</th>
      <td>sustained</td>
      <td>5</td>
      <td>5</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1000000.0,1929250,1991,25.0,25.0,2926,5,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>0.000000</td>
      <td>9.999500e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1714</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>104</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>70</td>
      <td>not non-inferior</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>70</td>
      <td>antibiotic</td>
      <td>108</td>
      <td>71</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.015670</td>
      <td>0.440092</td>
      <td>0.015670</td>
      <td>0.998962</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1715</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>24</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>16</td>
      <td>11</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>-0.229167</td>
      <td>0.112262</td>
      <td>-0.229167</td>
      <td>1.000000</td>
      <td>0</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1716</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>76</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>94.7 (87.1 to 98.5)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>31</td>
      <td>23</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.192275</td>
      <td>0.004854</td>
      <td>0.192275</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1717</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>5.00</td>
      <td>25.00</td>
      <td>vancomycin</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>3</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,25.0,3,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>0.625000</td>
      <td>4.027663e-03</td>
      <td>0.625000</td>
      <td>1.000000e+00</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>5.0</td>
      <td>1 day gap + 200 mg QD for 18 days</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>no</td>
      <td>177</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>124</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>124</td>
      <td>antibiotic</td>
      <td>179</td>
      <td>106</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>0.108386</td>
      <td>0.017908</td>
      <td>0.108386</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1718</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1719</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1720</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1721</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1722</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1723</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1724</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1725</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1726</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1727</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1728</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1729</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1730</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1731</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1732</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1733</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1734</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1735</th>
      <td>sustained</td>
      <td>5</td>
      <td>3</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1000000.0,1929250,1991,25.0,2926,3,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>-0.400000</td>
      <td>1.000000e+00</td>
      <td>-0.400000</td>
      <td>9.368845e-02</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1736</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.100000</td>
      <td>1.000000</td>
      <td>0.100000</td>
      <td>0.227565</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1737</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>50</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>50 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>10</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.033333</td>
      <td>0.999900</td>
      <td>0.033333</td>
      <td>0.441682</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1738</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.100000</td>
      <td>0.227565</td>
      <td>-0.100000</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1739</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>100</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>100 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>12</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>0</td>
      <td>antibiotic</td>
      <td>15</td>
      <td>1</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.066667</td>
      <td>0.292929</td>
      <td>-0.066667</td>
      <td>1.000000</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1740</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>10</td>
      <td>1</td>
      <td>100.0</td>
      <td>1000.0</td>
      <td>-0.033333</td>
      <td>0.441682</td>
      <td>-0.033333</td>
      <td>0.999900</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1741</th>
      <td>sustained</td>
      <td>8</td>
      <td>8</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>0.000000</td>
      <td>9.999200e-01</td>
      <td>sustained</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>200</td>
      <td>mg</td>
      <td>BID</td>
      <td>10.0</td>
      <td>200 mg</td>
      <td>antibiotic</td>
      <td>Tiacumicins B</td>
      <td>yes</td>
      <td>15</td>
      <td>therapeutic</td>
      <td>Recurrence Rate.</td>
      <td>negative</td>
      <td>participants</td>
      <td>1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 2</td>
      <td>1</td>
      <td>antibiotic</td>
      <td>12</td>
      <td>0</td>
      <td>200.0</td>
      <td>2000.0</td>
      <td>0.066667</td>
      <td>1.000000</td>
      <td>0.066667</td>
      <td>0.292929</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1742</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1743</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1744</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1745</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>1.00</td>
      <td>5.0</td>
      <td>0,0.2,1.0,1.0,1.0,1000000.0,1929250,1991,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1746</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1747</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1748</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1749</th>
      <td>sustained</td>
      <td>8</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>0.20</td>
      <td>1.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,0.2,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>1.525879e-05</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1750</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,1.0,1000000.0,1929250,1991,25.0,2926,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.765625e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1751</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,1.0,1000000.0,1929250,1991,25.0,2926,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.765625e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1752</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,1.0,1000000.0,1929250,1991,25.0,2926,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.765625e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1753</th>
      <td>sustained</td>
      <td>5</td>
      <td>0</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>NaN</td>
      <td>2926</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>5</td>
      <td>5</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>0,1.0,1000000.0,1929250,1991,25.0,2926,5,5,5,5.0,5.0,90.0,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-1.000000</td>
      <td>1.000000e+00</td>
      <td>-1.000000</td>
      <td>9.765625e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1754</th>
      <td>sustained</td>
      <td>8</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.875000</td>
      <td>1.000000e+00</td>
      <td>-0.875000</td>
      <td>2.593994e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>108</td>
      <td>therapeutic</td>
      <td>Global cure at end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>71</td>
      <td>NaN</td>
      <td>with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>20 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>71</td>
      <td>antibiotic</td>
      <td>104</td>
      <td>70</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.015670</td>
      <td>0.998962</td>
      <td>-0.015670</td>
      <td>0.440092</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1755</th>
      <td>sustained</td>
      <td>8</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.875000</td>
      <td>1.000000e+00</td>
      <td>-0.875000</td>
      <td>2.593994e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>16</td>
      <td>therapeutic</td>
      <td>initially cured, then relapsed</td>
      <td>negative</td>
      <td>participants</td>
      <td>11</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>18 Years to 99 Years Â (Adult, Older Adult)</td>
      <td>Phase 3</td>
      <td>11</td>
      <td>antibiotic</td>
      <td>24</td>
      <td>11</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>0.229167</td>
      <td>1.000000</td>
      <td>0.229167</td>
      <td>0.112262</td>
      <td>0</td>
      <td>0</td>
    </tr>
    <tr>
      <th>1756</th>
      <td>sustained</td>
      <td>8</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.875000</td>
      <td>1.000000e+00</td>
      <td>-0.875000</td>
      <td>2.593994e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>staggered age dependent dose, recorded &gt;6 years dosage</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>31</td>
      <td>therapeutic</td>
      <td>Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days</td>
      <td>positive</td>
      <td>Percentage of participants</td>
      <td>77.4 (58.9 to 90.4)</td>
      <td>NaN</td>
      <td>Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.</td>
      <td>All</td>
      <td>Child</td>
      <td>up to 17 Years Â (Child)</td>
      <td>Phase 3</td>
      <td>23</td>
      <td>antibiotic</td>
      <td>76</td>
      <td>71</td>
      <td>400.0</td>
      <td>4000.0</td>
      <td>-0.192275</td>
      <td>1.000000</td>
      <td>-0.192275</td>
      <td>0.004854</td>
      <td>1</td>
      <td>1</td>
    </tr>
    <tr>
      <th>1757</th>
      <td>sustained</td>
      <td>8</td>
      <td>1</td>
      <td>positive</td>
      <td>NaN</td>
      <td>Golden Syrian</td>
      <td>M</td>
      <td>hamster</td>
      <td>cumulative mortality</td>
      <td>therapeutic</td>
      <td>1.0</td>
      <td>ATCC9689</td>
      <td>NaN</td>
      <td>90.0</td>
      <td>1000000.0</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>1.00</td>
      <td>5.00</td>
      <td>Tiacumicins B</td>
      <td>therapeutic</td>
      <td>8</td>
      <td>8</td>
      <td>5.00</td>
      <td>25.0</td>
      <td>1,1.0,1.0,1000000.0,1929250,1991,25.0,5.0,5.0,8,8,8,90.0,ATCC9689,Golden Syrian,M,Tiacumicins B,clindamycin+challenge,cumulative mortality,hamster,nan,nan,nan,nan,positive,sustained,t,t,vancomycin</td>
      <td>-0.875000</td>
      <td>1.000000e+00</td>
      <td>-0.875000</td>
      <td>2.593994e-04</td>
      <td>sustained</td>
      <td>500.0</td>
      <td>5000.0</td>
      <td>125</td>
      <td>mg</td>
      <td>QID</td>
      <td>10.0</td>
      <td>NaN</td>
      <td>antibiotic</td>
      <td>vancomycin</td>
      <td>no</td>
      <td>179</td>
      <td>therapeutic</td>
      <td>sustained clinical cure 30 days after end of treatment</td>
      <td>positive</td>
      <td>participants</td>
      <td>106</td>
      <td>Superiority</td>
      <td>Cochran-Mantel-Haenszel</td>
      <td>All</td>
      <td>Adult, Older Adult</td>
      <td>60 Years and older Â (Adult, Older Adult)</td>
      <td>Phase 4</td>
      <td>106</td>
      <td>antibiotic</td>
      <td>177</td>
      <td>124</td>
      <td>400.0</td>
      <td>5600.0</td>
      <td>-0.108386</td>
      <td>1.000000</td>
      <td>-0.108386</td>
      <td>0.017908</td>
      <td>1</td>
      <td>1</td>
    </tr>
  </tbody>
</table>